The AtlasProteins
EGFR (epidermal growth factor receptor)
The receptor a skin cell uses to hear the signal to grow, found because a mouse protein opened newborn eyelids early, and the protein whose broken forms taught cancer medicine that one drug can be useless for most patients and transformative for a few.
- Not to be confused with
- eGFR, the estimated glomerular filtration rate, a calculation of kidney function from blood creatinine, with or without cystatin C, age and sex 3
- Gene and place
- EGFR, on the short arm of chromosome 7, band 7p11.2 4
- Protein
- A precursor of 1,210 amino acids: an outer ligand-binding region, one 23-amino-acid stretch through the membrane, and an inner tyrosine kinase followed by a tail 2,5
- Outer region
- Four domains; the ligand sits between domains I and III, and an arm from domain II grips the partner receptor 6
- How it switches on
- A ligand pairs two receptors; inside, one kinase switches on the other in an asymmetric dimer 7
- Ligands
- Seven: EGF, TGF-alpha, HB-EGF and betacellulin bind tightly; amphiregulin, epiregulin and epigen bind weakly 1
- Family
- ErbB/HER: EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) 2
- Key dates
- EGF isolated 1962; receptor binding 1975; kinase activity 1978; tyrosine identified as its target 1980; gene cloned 1984 5,8,9,10,11
- Viral relative
- v-erbB, the cancer gene of avian erythroblastosis virus, a truncated copy of the receptor 12
- Drugs aimed at it
- Kinase inhibitors: first generation gefitinib and erlotinib; second generation afatinib and dacomitinib; third generation osimertinib and lazertinib; for exon 20 insertions, sunvozertinib (mobocertinib failed its first-line phase 3 trial). Antibodies cetuximab and panitumumab; the EGFR-MET bispecific antibody amivantamab 2,13,14,15,16,17,18,19,20
In brief
What it is
EGFR is a protein that runs once through the outer membrane of a cell: its outer part catches growth factors, and its inner part is a tyrosine kinase, an enzyme that fastens phosphate groups onto the amino acid tyrosine, on itself and on other proteins, to pass the signal inward 2,11. It is made as a chain of 1,210 amino acids, with a single 23-amino-acid stretch crossing the membrane, from a gene on the short arm of chromosome 7, at band 7p11.2 4,5. It is the first of four related receptors, the ErbB family, named after the erbB cancer gene of a bird virus and also called the HER family, for human epidermal growth factor receptor, which is why it is also called ErbB1 and HER1 1,2,12. It is not eGFR, the estimated glomerular filtration rate on a kidney report, which is a calculation of kidney function from a blood test 3.
Why it matters
When gefitinib, a pill that blocks the receptor's kinase, was given accelerated approval in 2003 for advanced lung cancer that had progressed after platinum and docetaxel chemotherapy, with no test to choose who received it, about one patient in ten responded 21. In 2004 three groups showed that the responders' tumors carried mutations in the kinase itself, and five years later a trial that chose patients by their clinical features rather than their genes found that those without the mutation progressed sooner on the pill than on chemotherapy 22,23,24,25. Testing became the price of entry: in 2015 the US Food and Drug Administration approved gefitinib again, this time only for tumors carrying the mutations 26. With osimertinib plus chemotherapy in the FLAURA2 trial, median survival reached 47.5 months, just under four years, and in the MARIPOSA trial 60% of patients given the antibody amivantamab with the pill lazertinib were alive at three years 27,28. In colorectal cancer the same receptor taught the opposite lesson: antibodies against it do nothing when the KRAS protein beneath it is stuck on 29,30.
When it is lost
The first child reported with no working receptor, a boy whose parents each passed him a broken copy, had skin that eroded, scaled and lost its hair in his first year, then broke out in papules and pustules like the rash of patients on EGFR-blocking drugs; his bowel and lungs were inflamed, and he died at two and a half of skin and chest infections and disordered blood salts 31. Drugs that block the receptor reproduce parts of that picture: rash or acne in 66.2% of patients given gefitinib in one large trial and 74.8% of those given panitumumab in another, diarrhea in 46.6% on gefitinib, and falling blood magnesium, lost through the kidney, in 95 of 98 colorectal cancer patients given antibodies against the receptor 25,32,33.
When it is stuck on
In about half of advanced lung adenocarcinomas from Asian patients (51.4% in a 2014 survey across seven Asian regions, though 22.2% in India), against 8% of non-small-cell lung cancers from non-East Asian patients in a 2005 four-country series, an EGFR mutation leaves the kinase running and the tumor dependent on it; most often it is a small deletion in exon 19, one of the gene's coding blocks, or the swap of arginine for leucine at position 858 (L858R) 24,34,35. In glioblastoma the gene is copied many times over and often missing a block of its outer part, the variant called EGFRvIII 36,37,38. A bird virus, avian erythroblastosis virus, carries a truncated version of the receptor as its cancer gene 12. And outside cancer, increased signaling through the receptor is implicated in Ménétrier disease, an overgrowth of the stomach lining that improved on the antibody cetuximab in a small uncontrolled trial 39.
The skin and the tumor lean on the same receptor, which is why, with several of these drugs, the patients with the worst rash have tended to live longest 40,41.
What EGFR is, and the kidney number it is not
Every lining of the body, the skin, the gut, the airways, has to keep renewing itself without overgrowing, and the cells that do it take part of their instructions from outside, as small proteins called growth factors 2. EGFR is one of the receptors that hears those instructions, and the signaling it carries is, in the words of the group that described the first child known to be born without a working receptor, "fundamentally important for tissue homeostasis," the steady balance between cells lost and cells made 31.
The receptor is a single protein chain that passes once through the cell's outer membrane 5. The gene's code, read in full in 1984, specifies a precursor of 1,210 amino acids, with a stretch of 23 that crosses the membrane and separates an outer part that binds the growth factor from an inner part that does the work 5. The outer part is coated with sugars; the inner part is a kinase, an enzyme that takes a phosphate group from ATP, the cell's energy molecule, and attaches it to a protein, followed by a tail 2. EGFR's kinase attaches the phosphate to tyrosine, one of the twenty amino acids, which makes it a tyrosine kinase; its drug-binding pocket is the pocket where ATP binds 11,22.
The gene sits on the short arm of chromosome 7, at band 7p11.2 4. EGFR is the first of four related receptors, numbered ErbB1 to ErbB4 and also called HER1 to HER4, for human epidermal growth factor receptor 1,2. The ErbB name echoes v-erbB, the cancer gene of avian erythroblastosis virus, a virus of birds, whose protein turned out in 1984 to be a cut-down copy of this receptor 5,12.
One warning about letters. On a kidney report, eGFR with a small e is the estimated glomerular filtration rate, a calculation of how much blood the kidneys filter, made from the blood level of creatinine, a waste product of muscle that healthy kidneys clear, sometimes with cystatin C, a small protein that all cells make and the kidneys filter, plus age and sex; since 2021 the standard equations no longer include race 3. It has nothing to do with the receptor: a low eGFR is not an EGFR mutation, and an EGFR mutation in a tumor says nothing about kidney function, although antibodies that block the receptor do change how the kidney handles magnesium 3,33,42.
In three sentences each
A growth factor makes two receptors embrace
The outer part of the receptor has four domains 6. A growth factor such as EGF docks between domains I and III, which swings out an arm from domain II that grips a second receptor, so that two receptor-ligand pairs sit back to back with the ligands on the outside 2,6.
One kinase switches on the other
On its own the inner kinase is held in an inactive shape 7. In a pair, the lower lobe of one kinase presses against the upper lobe of its partner and switches it on, the way the protein cyclin switches on a cyclin-dependent kinase, one of the enzymes that drive a cell through division; this asymmetric dimer was described in 2006 from crystal structures and cell experiments 2,7.
The signal runs down through RAS
The active receptor feeds three main relays: the RAS-RAF-MEK-ERK chain, four proteins in a row that carry growth orders to the nucleus; the PI3K-AKT chain, made of phosphoinositide 3-kinase and the kinase AKT, which tells cells to survive and grow; and phospholipase C gamma, an enzyme that splits a membrane fat into chemical messengers 2. When KRAS, the first link of the RAS chain and the one just below the receptor, is mutated and stuck on, blocking the receptor above it no longer helps, which is why colorectal tumors are tested for RAS before antibodies against EGFR are given 29,43.
Feedback reopens a closed door
When a drug blocks BRAF, a link below RAS, in colon cancer cells, EGFR is rapidly reactivated and keeps the cells growing; melanoma cells, which make little EGFR, lack that escape 44. In a 2025 trial in BRAF-mutant colorectal cancer, a BRAF inhibitor given with cetuximab and chemotherapy roughly doubled median survival compared with standard care at an interim analysis, 30.3 against 15.1 months (hazard ratio 0.49); the trial was funded by Pfizer and others 45.
The words, defined
- Receptor
- A protein, usually on the cell surface, that recognizes a specific outside signal and changes shape in response.
- Ligand
- The molecule a receptor recognizes; for EGFR, a growth factor such as EGF.
- Kinase
- An enzyme that moves a phosphate group from ATP onto another molecule, switching that molecule's activity on or off.
- Tyrosine kinase
- A kinase that attaches the phosphate to the amino acid tyrosine.
- Exon
- A stretch of a gene that is kept in the final message and codes for part of the protein; EGFR's lung cancer mutations cluster in exons 18 to 21.
- eGFR
- Estimated glomerular filtration rate, a kidney-function number. Unrelated to EGFR.
Found by watching newborn mice open their eyes
In 1962 Stanley Cohen described a protein from the submaxillary salivary gland of mice that made newborn mice open their eyelids and cut their incisor teeth early 8. In 1975 H. Gregory published the "isolation and structure of urogastrone," a gastrointestinal hormone, "and its relationship to epidermal growth factor" 46. The protein became known as epidermal growth factor, the title Cohen gave his Nobel lecture in 1986 47. He shared that prize, the 1986 Nobel Prize in Physiology or Medicine, with Rita Levi-Montalcini, whose own lecture told the story of nerve growth factor 47,48,49.
A growth factor has to be received. In 1975 Graham Carpenter and Cohen, with two colleagues, labeled EGF with radioactive iodine and showed that human fibroblasts, the cells that make connective tissue, bound it specifically and to saturation, meaning that binding stopped rising once a fixed number of sites was filled, about 100,000 molecules per cell, and so tightly that half the sites filled at a concentration below one billionth of a mole per liter; cells from humans, mice, rats and chickens all had the receptor 9. In 1978 they showed that EGF switched on an enzyme in cell membranes that attached phosphate to proteins 10, and in 1980 Hideo Ushiro and Cohen found that the phosphate went onto tyrosine, with only traces, if any, on the more usual amino acids serine and threonine; the purified receptor-enzyme complex did it by itself 11. The receptor and the kinase were one molecule 11.
In 1984 two papers tied that molecule to cancer 5,12. Julian Downward and colleagues sequenced six fragments of the purified human receptor, 83 amino acids in all, and found that 74 matched the protein made by v-erbB, the cancer gene of avian erythroblastosis virus; they proposed that the virus had captured a truncated receptor without its outer, growth-factor-binding part 12. Axel Ullrich and colleagues then published the full sequence from human placenta and from A431 cells, a line grown from a human epidermoid carcinoma, a skin-type (squamous) cancer, confirmed the match, and found the gene amplified and apparently rearranged in A431 cells so that they made a shortened message coding only for the outer part 5. A year later the same circle of laboratories found the gene amplified in human glial brain tumors, tumors of the brain's supporting cells 36.
The structure came later 6,7. In 2002 a crystal structure showed how EGF binds the outer region and how two receptors hold each other 6, and in 2006 John Kuriyan's group showed how one inner kinase switches on the other 7. By then the receptor had already been drugged 21.
1962Seen
A salivary protein opens eyelids
Cohen isolates a mouse submaxillary gland protein that hastens eyelid opening and incisor eruption in newborn mice 8.1975Seen
The receptor is detected
Radiolabeled EGF binds human fibroblasts specifically, about 100,000 sites per cell 9.1978Explained
It is an enzyme
EGF stimulates phosphorylation in isolated membranes 10.1980Explained
The target is tyrosine
The EGF-activated kinase phosphorylates tyrosine, with only traces, if any, on serine or threonine 11.1984Explained
A viral cancer gene is a stolen receptor
74 of 83 receptor amino acids match the v-erbB protein of avian erythroblastosis virus 12.1984Seen
The gene is cloned
The full 1,210-amino-acid precursor is sequenced; the gene is amplified in A431 cancer cells 5.1985Seen
Amplified in brain tumors
Four of ten glial tumors with high receptor levels carry amplified genes 36.1986Seen
1990Seen
EGFRvIII
Six glioblastomas share one aberrant message that skips exons 2 to 7 37.2003Approved
Gefitinib, without a test
US Food and Drug Administration (FDA) accelerated approval in lung cancer after chemotherapy, on a 10.6% response rate 21.2004Overturned
2005Trial
2005Explained
2005Seen
T790M can be inherited
In a family with several lung cancers, T790M is passed down through the germline and present in every cell 54.2006Trial
Cetuximab with radiation
Adding cetuximab to radiation prolongs survival in head and neck cancer 55.2006Explained
The asymmetric dimer
One kinase activates its partner the way cyclin activates a cyclin-dependent kinase 7.2008Overturned
2009Overturned
IPASS
Without the mutation, gefitinib is worse than chemotherapy; selection by mutation replaces selection by appearance 25.2010Trial
Chosen by gene, not looks
NEJ002: in 230 patients with mutations, gefitinib doubles median progression-free survival over chemotherapy, 10.8 vs 5.4 months 56.2013Overturned
All RAS, not just KRAS exon 2
Other RAS mutations also predict no benefit from panitumumab 43.2013Trial
Second generation
Afatinib, an irreversible blocker of EGFR, HER2 and HER4, beats cisplatin-pemetrexed in LUX-Lung 3 17.2014Overturned
More is not better
RTOG 0522: adding cetuximab to cisplatin and radiation in 891 head and neck cancer patients does not improve outcome 57.2015Approved
Gefitinib returns, for the mutation only
FDA approval restricted to exon 19 deletions or L858R found by an approved test 26.2015Explained
C797S
Plasma sequencing finds C797S (cysteine replaced by serine at position 797), a mutation that defeats osimertinib 58.2017Trial
2017Trial
ARCHER 1050
Dacomitinib beats gefitinib on median progression-free survival, 14.7 vs 9.2 months 18.2018Overturned
2020Trial
2023Trial
2023Trial
2024Trial
2024Overturned
Immunotherapy adds little
KEYNOTE-789: pembrolizumab with chemotherapy after EGFR pills improves neither progression nor survival significantly 69.2025Overturned
An exon 20 pill fails its test
EXCLAIM-2: mobocertinib no better than chemotherapy, 9.6 vs 9.6 months 19.2025Trial
2025Trial
2025Explained
Never-smokers' genomes
In Sherlock-Lung, never-smokers from more polluted regions carry more mutations in their lung cancers 72.2026Trial
SACHI
Savolitinib plus osimertinib beats chemotherapy where MET is amplified at resistance 73.2026Trial
Exon 20 pill first-line
Sunvozertinib beats chemotherapy on progression-free survival 15.2026Trial
- Tumor DNA testing for EGFR mutationsThe tumor's DNA, from a biopsy or a cytology sample (loose cells drawn through a needle or from fluid), is read for exon 19 deletions, the L858R substitution, exon 20 insertions and resistance mutations; staining the tumor for EGFR protein is not recommended for this purpose 42.Lung adenocarcinoma before an EGFR drug is chosen, now including resected and stage III disease, where osimertinib has trial evidence, and, since the 2025 NeoADAURA trial, before surgery 42,64,68,70In IPASS the mutation was the strongest predictor of benefit, and the predictive value of gene copy number was driven by coexisting mutation in a post hoc analysis 89; protein staining is not recommended for this purpose 42.Tissue is sometimes too scant to test, which is the gap plasma testing is endorsed to fill 42,102,103.
- Plasma tumor DNA (liquid biopsy)Fragments of tumor DNA circulating in blood are tested for the same mutations 103.The first liquid biopsy test approved by the US Food and Drug Administration (FDA) was for EGFR mutations; now used at diagnosis when tissue is limited and at progression to look for the resistance mutations T790M or C797S 42,58,102When plasma finds a mutation it can be acted on, but plasma misses some mutations that tissue would find, so agreement runs one way: a positive result rules in, a negative does not rule out 42,102,103.The guideline endorses plasma to rule a mutation in, not out: a negative result needs tissue 42.
- EGFR copy number (amplification)Counting copies of the gene, by fluorescence in situ hybridization (glowing DNA probes counted under the microscope) or by sequencing, finds amplification, the hallmark of EGFR in glioblastoma, present in about half of newly diagnosed cases 36,81,83.Glioblastoma trials, the grading of some IDH-mutant gliomas (gliomas with a mutation in the enzyme isocitrate dehydrogenase), and research in lung cancer 38,96,112In lung cancer, high copy number without a mutation went with shorter progression-free survival on gefitinib than on chemotherapy in a post hoc analysis, not longer 89; amplification alongside a mutation was linked to shorter progression-free survival on osimertinib in a 2026 retrospective cohort 96.In glioblastoma, choosing patients by amplification or EGFRvIII has not produced a survival benefit in a randomized trial: ACT IV, a vaccine against EGFRvIII, gave a hazard ratio of 1.01, and INTELLANCE-1, an antibody-drug conjugate tested in 639 patients, a median of 18.9 against 18.7 months at its interim analysis (hazard ratio 1.02) 38,83.
- RAS testing before anti-EGFR antibodiesIn colorectal cancer the decisive test is not of EGFR at all but of KRAS and NRAS, two members of the RAS family of switch proteins, beneath it 30,43.Recommended by a joint pathology and oncology guideline before cetuximab or panitumumab in metastatic colorectal cancer 107In a retrospective analysis of a randomized trial, cetuximab gave no survival benefit in tumors with KRAS exon 2 mutations (hazard ratio 0.98) 29.Testing only KRAS exon 2 missed the 17% of tumors in the PRIME trial that were normal at exon 2 but carried other KRAS or NRAS mutations 43.
- Serum magnesium during antibody treatmentAntibodies against EGFR block magnesium recovery in the kidney 33,76.Measured during treatment with cetuximab or panitumumab, because the fall is common and progressive 33,76Serum magnesium fell in 97% of patients in one prospective cohort 33.The fall is gradual, so the prospective study tracked its slope over months rather than relying on a single value 33.
Seven keys, four locks, and a kinase that needs a partner
Seven growth factors fit EGFR: EGF itself, transforming growth factor alpha (TGF-alpha), heparin-binding EGF-like growth factor, betacellulin, amphiregulin, epiregulin and epigen 1. The first four bind tightly and the last three weakly 1. EGF itself is made as a larger precursor, pro-EGF, and where the cell delivers it matters: in one inherited kidney disease the precursor is made but not delivered to the blood-facing side of kidney cells, and the receptor there goes unstimulated 76.
The outer region of the receptor has four domains 6. In the crystal structure published in 2002, domains I to III form a C shape, EGF docks between domains I and III, and an arm from domain II reaches out and holds the body of a second receptor 6. Binding of the growth factor causes the large change of shape that exposes that arm; two receptor-ligand pairs then join back to back, with the ligands on the outside of the pair 2. The ligand does not bridge the two receptors; it reshapes each one so that they can grip each other 6.
Inside, the kinase is held shut on its own, in a shape like that of the inactive forms of Src, another tyrosine kinase, and of the cyclin-dependent kinases, enzymes that drive cell division 7. In 2006 Xuewu Zhang and John Kuriyan showed that crowding the kinase domains together, or mutating a leucine in the flexible activation loop, was enough to switch it on, and that the switch is an asymmetric pair: the lower, C-terminal lobe of one kinase presses against the upper, N-terminal lobe of the other, in the way the protein cyclin turns on a cyclin-dependent kinase 7. The activator stays the activator and the receiver becomes active, which explains how a pair of identical receptors, or EGFR paired with a relative, can turn itself on 2,7.
Once on, the receptor phosphorylates tyrosines on itself and on other proteins 11, and the signal leaves along three main relays: the RAS-RAF-MEK-ERK chain, the PI3K-AKT chain (phosphoinositide 3-kinase and the kinase AKT) and phospholipase C gamma 2. KRAS, the protein at the top of the first chain, is the subject of its own entry; whether it is normal or mutated decides whether blocking EGFR above it can work 29.
The other three family members are odd on their own 2. HER2 binds no growth factor at all, and HER3's kinase barely works, yet the pair of HER2 with HER3 is the strongest signaling complex in the family 2. HER2 is the target of trastuzumab, an antibody used in breast cancer 77. EGFR, in other words, is one corner of a network rather than a single wire 77, and advanced cancers treated with drugs aimed at one corner of it usually become resistant, often by rerouting the signal through another receptor 2,78.
The words, defined
- Dimer
- A pair of protein molecules working as a unit; a homodimer is two of the same, a heterodimer two different ones.
- TGF-alpha
- Transforming growth factor alpha, a growth factor that binds EGFR; unrelated in action to the better-known TGF-beta.
- Activation loop
- A flexible segment of a kinase whose position decides whether the enzyme's active site is open.
- Allosteric activation
- Switching an enzyme on by binding at a site other than its active site, here by the touch of a partner kinase.
- RAS-RAF-MEK-ERK
- A chain of signaling proteins, each switching on the next, that carries growth signals from the membrane to the nucleus. The letters are protein names: RAS from rat sarcoma, RAF from rapidly accelerated fibrosarcoma, MEK from MAPK/ERK kinase, ERK from extracellular signal-regulated kinase.
- PI3K-AKT
- A signaling chain of phosphoinositide 3-kinase, an enzyme that tags a membrane fat, and AKT, a kinase it switches on; it tells cells to survive and grow.
- Phospholipase C gamma
- An enzyme that splits a fat in the cell membrane into two messenger molecules, one of which releases calcium inside the cell.
What the skin, gut, kidney and stomach use it for
Much of what is known about EGFR's ordinary job comes from what goes wrong when it is taken away 31,79. Because skin depends on EGFR signaling, skin toxicity is the characteristic and frequent cost of drugs that block it, severe enough at times to force a lower dose or a pause in cancer treatment 79.
The plainest evidence comes from one child 31. In 2014 a London group reported a boy with two copies of the same inherited mutation, which changed glycine 428 to aspartate and left the receptor unable to be phosphorylated or to signal; it was the first primary inherited defect of EGFR to be recorded 31. In his first year his skin showed erosions, dry scale and hair loss, then papules and pustules (raised bumps and pus-filled spots) like the rash of patients on EGFR-blocking drugs; his skin cells matured too early, inflammatory and innate immune programs (the body's first-line, nonspecific defenses) were switched on, and his bowel and lungs were inflamed as well 31. He died at two and a half of extensive skin and chest infections and a disordered balance of blood salts 31. In 2015 a Philadelphia group reported two siblings with the same homozygous mutation who were born prematurely with abnormal skin and hair, suffered failure of several organs and died as newborns of perforation of the intestine; EGF could not switch on the mutant receptor in cells grown from the patients, and a comparison with a separately reported patient of the same ethnic background and genotype supported the mutation as the cause 80. Three children are still very few, but together they read like a long-term version of what the drugs do 31,79,80.
The kidney uses the receptor to hold on to magnesium 76. In 2007 a Dutch group traced an inherited form of isolated renal magnesium wasting to a mutation in the EGF gene that stops the precursor reaching the blood-facing side of kidney cells, so the receptor there is not stimulated and TRPM6, the epithelial magnesium channel, is not switched on; patients treated with cetuximab developed low magnesium too 76. In a prospective study of 98 colorectal cancer patients given antibodies against the receptor, serum magnesium fell in 95, or 97%, and urine collections and intravenous magnesium loading showed a defect in reabsorption by the kidney, while 16 patients on chemotherapy alone showed no such fall 33. EGF, in other words, behaves as a magnesium-retaining hormone 76.
The gut shows it more mildly: diarrhea occurred in 46.6% of patients given gefitinib in the IPASS trial, whereas the main problems with chemotherapy were nerve damage, low white cell counts and hair loss 25.
Too much signaling has a cost as well 39. In Ménétrier disease, a rare premalignant overgrowth of the stomach lining, increased EGFR signaling has been implicated; in a single-arm trial at Vanderbilt in 9 patients sick enough that removal of the stomach was being considered, all 7 who completed a month of cetuximab improved in quality of life, in the mass of acid-making parietal cells and in acid output, and 4 later showed near-complete remission under the microscope 39. Without a control group, the trial cannot say how much of that was the drug, but the direction of change matches the mechanism 39.
The words, defined
- Homozygous
- Carrying the same variant on both copies of a gene, one from each parent.
- TRPM6
- A channel protein in the kidney and gut through which magnesium is absorbed into cells.
- Hypomagnesemia
- A low concentration of magnesium in the blood.
- Ménétrier disease
- A rare premalignant disorder in which the stomach lining overgrows and the acid-making parietal cells dwindle.
- Single-arm trial
- A study in which every patient gets the treatment, so there is no comparison group.
Glioblastoma: the most altered receptor, and the least rewarding target
In 1985 the laboratories that had just cloned the receptor found that 4 of 10 glial brain tumors with more receptor than normal also had the gene amplified, meaning copied many times over on the chromosome 36. In 1990 a Stockholm group showed that in six glioblastomas the amplified genes had been broken in different places yet produced the same faulty message, in which exon 1 is joined directly to exon 8; the resulting protein lacks 801 bases' worth of code from exons 2 to 7, a large block of its outer region, but keeps the rest in frame, so the remaining code is still read correctly 37. That variant is now called EGFRvIII 38. The Cancer Genome Atlas, a US national project that catalogs the DNA changes of tumors, analyzing more than 500 glioblastomas in 2013, found complex rearrangements of EGFR among the tumor's signature changes 81; a 2012 study put oncogenic EGFR alterations in about 40% of glioblastomas 82, and a 2023 phase 3 trial reported EGFR amplification in about half of newly diagnosed glioblastomas 83.
That should have made glioblastoma the obvious target. It did not. In EORTC 26034, a randomized phase 2 trial published in 2009, 110 patients with recurrent glioblastoma were given erlotinib, one of the first-generation kinase inhibitors, the original pills aimed at the receptor's ATP pocket, or temozolomide or carmustine chemotherapy: 11.4% on erlotinib were alive without progression at six months against 24% on chemotherapy, and no tumor marker examined, EGFRvIII among them, clearly picked out patients who did better 84. A Memorial Sloan Kettering-led group offered a mechanical reason in 2012 82. Erlotinib-type drugs bind the active shape of the kinase, which suits the kinase mutations of lung cancer; glioblastoma's mutations and deletions sit in the outer region, and those mutant receptors were poorly inhibited by such drugs, whereas drugs that bind the inactive shape inhibited them potently and killed the glioblastoma cells in culture and in mice 82. That is laboratory evidence for why one class of drug failed, not proof that another class will succeed in patients 82.
The attempts to aim the immune system or a toxin at the receptor have been just as sobering 38,83. ACT IV tested rindopepimut, a vaccine against the EGFRvIII protein, with temozolomide chemotherapy in 745 patients with newly diagnosed EGFRvIII-positive glioblastoma; it was stopped for futility, that is, stopped early because it could no longer succeed, and in patients with little residual tumor the median survival was 20.1 months with the vaccine and 20.0 months without (hazard ratio 1.01) 38. The trial was funded by Celldex Therapeutics, several of whose employees were authors 38. In INTELLANCE-1, 639 patients with newly diagnosed EGFR-amplified glioblastoma received radiation and temozolomide with depatuxizumab mafodotin, an antibody carrying a cell-killing drug to cells with normal (wild-type) EGFR or EGFRvIII, or with placebo: an interim analysis found no survival gain, a median of 18.9 against 18.7 months (hazard ratio 1.02), although progression-free survival was modestly longer, 8.0 against 6.3 months, and damage to the surface of the cornea occurred in 94% of treated patients; several authors were AbbVie employees 83,85.
Drug delivery across the barrier between blood and brain is one of the obstacles 85, and the newest approaches go around it. In 2024 a Massachusetts General Hospital team infused CAR T cells, T cells (white blood cells that recognize and kill infected or abnormal cells) engineered to recognize EGFRvIII and to secrete a second molecule that steers other T cells toward ordinary EGFR, directly into the fluid spaces of the brain in three patients with recurrent glioblastoma; tumors shrank dramatically within days, but in two of the three the response did not last 86. Also in 2024, a University of Pennsylvania team infused CAR T cells aimed at both EGFR and a second target, IL13Rα2 (interleukin-13 receptor alpha 2), into the spinal fluid of six patients with recurrent glioblastoma: tumors shrank on early scans in all six, none met formal response criteria, and all had early neurotoxicity that needed high-dose steroids and anakinra, a drug that blocks the receptor for the inflammatory signal interleukin-1; two authors worked for Kite Pharma, a Gilead company 87. In October 2026 a Duke group reported a phase 1 trial in which an antibody-toxin conjugate against both forms of the receptor was infused directly into the tumor in 81 patients; the median survival of the 72 with IDH-wild-type recurrent glioblastoma was 7.9 months, and the biomarkers, measurable signs in tumor or blood, linked with longer survival came from univariate analyses, which look at one factor at a time without allowing for the others, in an uncontrolled study; the authors' own conclusion that the drug prolongs survival in a subset goes further than a trial without a control group can show 88. None of the three is yet evidence that patients live longer than they would have without it 86,87,88.
The words, defined
- Glioblastoma
- A fast-growing cancer of the brain's glial cells, the cells that support and nourish nerve cells.
- Gene amplification
- Extra copies of a stretch of DNA, sometimes dozens, so that a cell makes far more of the encoded protein.
- EGFRvIII
- EGFR variant III, a form missing exons 2 to 7 of its outer region, found in glioblastoma.
- CAR T cells
- A patient's own T cells, engineered with a chimeric antigen receptor that makes them recognize a chosen target on tumor cells.
- Antibody-drug conjugate
- An antibody with a toxic drug attached, used to deliver the drug to cells that carry the antibody's target.
- IDH-wild-type
- A glioma without mutation of the isocitrate dehydrogenase genes, the group that includes true glioblastoma in adults.
- Phase 1, 2 and 3 trials
- Phase 1 tests safety and dose in a few patients; phase 2 looks for a signal of benefit; phase 3 compares the treatment with the standard in a large randomized trial.
- Interim analysis
- A planned look at the results before a trial is finished.
- Hazard ratio
- How fast an event, such as progression or death, happens in one group compared with another; 0.5 means half the rate, 2 means twice.
- Progression-free survival
- Time until the cancer grows or the patient dies, whichever comes first.
Lung cancer: one pill, two opposite answers
Gefitinib, a small molecule that blocks the receptor's kinase from inside the cell, was given accelerated approval by the US Food and Drug Administration on 5 May 2003, for advanced non-small-cell lung cancer that had progressed after both platinum chemotherapy and docetaxel 21. The evidence was a response rate: tumors shrank by at least the agreed amount in 10.6% of patients, 15 of 142, and responses were more frequent in women and in nonsmokers 21. Two large trials adding gefitinib to chemotherapy in 1,093 and 1,037 patients had shown no benefit at all, and lung inflammation, interstitial lung disease, had occurred in about 1% worldwide and 2% in Japan, fatal in about a third of cases 21. The FDA's own reviewers wrote that no controlled trial had yet shown that the drug improved symptoms or survival, that the drug often called a selective EGFR inhibitor in fact inhibited several other tyrosine kinases at concentrations reached in patients, and that no clinical study had linked the amount of EGFR in a tumor to response 21. Twelve years later the same agency approved gefitinib again, on 13 July 2015, but only for tumors with exon 19 deletions or L858R found by an FDA-approved test, on a 50% response rate in 106 untreated patients with such mutations 26.
The controlled trials came in 2005, and they disagreed 50,51. In BR.21, 731 unselected patients were given erlotinib, a close relative of gefitinib, or placebo after chemotherapy: 8.9% responded, against less than 1% on placebo, and median survival was 6.7 against 4.7 months, a hazard ratio of 0.70 50. In ISEL, 1,692 patients were given gefitinib or placebo: median survival was 5.6 against 5.1 months, a hazard ratio of 0.89 that missed statistical significance, although preplanned subgroups of never-smokers and patients of Asian origin lived several months longer on the drug 51. A small fraction of patients was getting a large benefit, and an average was hiding them 22,51.
The explanation had already arrived, in April 2004 22. Thomas Lynch, Daniel Haber and colleagues at Massachusetts General Hospital noted that about 10% of patients had rapid, often dramatic responses, sequenced the receptor gene, and found mutations in the kinase domain in 8 of 9 responders and 0 of 7 nonresponders; the mutations were small deletions or single substitutions clustered around the pocket where ATP binds, and in cultured cells they made the receptor more active and more sensitive to gefitinib 22. On the same day, a Dana-Farber group reported such mutations in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States 23. In August, William Pao, Harold Varmus and colleagues at Memorial Sloan Kettering found the same two families of mutation, in-frame deletions in exon 19, losses of code that leave the rest of the message readable, and substitutions at codon 858 in exon 21, the three-letter unit of code for amino acid 858, in 7 of 10 tumors sensitive to gefitinib and 5 of 7 sensitive to erlotinib, and in none of 18 that were resistant 24.
The trial that turned the finding into practice was designed before it was understood 25. IPASS randomized 1,217 previously untreated East Asian patients with adenocarcinoma who had never smoked or had smoked lightly, features that earlier uncontrolled studies had linked to benefit, to gefitinib or carboplatin-paclitaxel chemotherapy 25. Overall, gefitinib won on progression-free survival (hazard ratio 0.74), with 24.9% against 6.7% free of progression at 12 months 25. But inside that average were two opposite trials 25. In the 261 patients whose tumors carried a mutation, the hazard ratio was 0.48, strongly favoring gefitinib; in the 176 whose tumors did not, it was 2.85, strongly favoring chemotherapy 25. Selecting by appearance had enriched the trial for the mutation, but it had also given the pill to a large group of patients who looked the part, lacked the mutation and did worse on it than on chemotherapy 25.
Overall survival in IPASS did not differ between the arms, even in patients with a mutation (hazard ratio 1.00), most likely because 64.3% of mutation-positive patients first given chemotherapy went on to receive an EGFR inhibitor later 89. The biomarker analysis added a second lesson: tumors with many copies of the gene but no mutation had shorter progression-free survival on gefitinib than on chemotherapy (hazard ratio 3.85), and in a post hoc analysis, one chosen after the data were seen, the predictive value of copy number was driven by coexisting mutation 89. The 2018 pathology guideline later recommended against protein staining for choosing EGFR treatment 42. Since then, the test that decides treatment has been a reading of the gene's sequence, not a measure of how much receptor the tumor makes 42.
Trials that enrolled only patients with the mutation followed. In NEJ002, run by Japanese centers, 230 patients with mutations were given gefitinib or carboplatin-paclitaxel: median progression-free survival was 10.8 against 5.4 months (hazard ratio 0.30), 73.7% against 30.7% responded, median survival was 30.5 against 23.6 months, a difference that was not statistically significant, and one patient on gefitinib died of interstitial lung disease 56. A second generation of irreversible pills, which bond permanently to the receptor, came next: afatinib, which also blocks HER2 and HER4, beat cisplatin-pemetrexed in LUX-Lung 3 (median progression-free survival 11.1 against 6.9 months, hazard ratio 0.58), and dacomitinib beat gefitinib in ARCHER 1050 (14.7 against 9.2 months, hazard ratio 0.59), with more severe acneiform rash, 14% against none; the first trial had Boehringer Ingelheim employees among its authors, and the second was funded by SFJ Pharmaceuticals and Pfizer 17,18.
The words, defined
- Non-small-cell lung cancer
- The large group of lung cancers that are not small-cell; adenocarcinoma, the type that arises from mucus-making and alveolar cells, is the commonest.
- Accelerated approval
- An FDA approval based on an early measure, such as tumor shrinkage, that is expected to predict real benefit, on condition that later trials confirm it.
- Response rate
- The share of patients whose tumors shrink by at least a set amount, usually 30% in summed diameter.
- Exon 19 deletion and L858R
- The two classic sensitizing EGFR mutations: a small in-frame loss of code in exon 19, and the substitution of arginine for leucine at position 858 in exon 21.
Who carries the mutation: never-smokers, East Asian patients and women, in numbers
The portrait that emerged in 2004 has held up, but it is a statistical portrait and not a rule 34,35. In 2005 a Dallas-led study sequenced 617 non-small-cell lung cancers from Japan, Taiwan, the United States and Australia and found kinase-domain mutations in 21%: in 51% of never-smokers against 10% of ever-smokers, 40% of adenocarcinomas against 3% of other types, 30% of East Asian patients against 8% of others, and 42% of women against 14% of men 35. None was found in the normal lung tissue of the same patients, and none of the tumors with an EGFR mutation also had a KRAS mutation, which suggests the two are alternative routes to the same disease 35.
The PIONEER study in 2014 tested 1,482 patients with newly diagnosed advanced adenocarcinoma in seven Asian regions prospectively, and 51.4% of the 1,450 evaluable tumors carried a mutation 34. The rate was 61.1% in women and 44.0% in men, 60.7% in never-smokers, and it fell with smoking, to 31.4% in people with more than 50 pack-years; it was 22.2% in India against 47.2% to 64.2% elsewhere 34. Once smoking was taken into account, sex no longer mattered statistically, which suggests that much of women's higher rate reflects differences in smoking 34. A 2015 review of 151 studies and 33,162 patients put the rate at 47% in the Asia-Pacific group, with a range from 20% to 76%, and 12% in Oceania, higher in women and never-smokers in every region, and noted that Africa, the Middle East, Central Asia and Central and South America were barely studied 90. Both of these large summaries had employees of AstraZeneca, which markets gefitinib, among their authors 21,34,90.
Why EGFR-driven cancers arise in people who never smoked is partly addressed by a 2023 study from the Francis Crick Institute and collaborators 91. It brought together three kinds of evidence of different strength 91. In people, fine particulate air pollution (PM2.5) was associated with the incidence of EGFR-driven lung cancer across 32,957 cases in four cohorts, an association that cannot by itself prove cause 91. In mice, pollutants drew macrophages, scavenger immune cells, into the lung that released the inflammatory signal interleukin-1 beta, which pushed alveolar cells, the cells lining the air sacs, already carrying an EGFR mutation into a progenitor-like state, resembling the immature cells that replenish tissue, that fed tumor growth 91. And in histologically normal lung tissue, normal under the microscope, from 295 people, deep sequencing, reading the same stretch of DNA many times to catch rare mutations, found EGFR driver mutations, mutations that push a cell toward cancer, in 18% of samples and KRAS driver mutations in 53% 91. The proposal is that pollution acts, at least in part, as a promoter on mutations many healthy people already carry 91.
A 2025 study of the tumor genomes of 871 never-smokers from 28 places, the Sherlock-Lung study, complicates that picture 72. Never-smokers account for around a quarter of lung cancers; EGFR mutations were more common in the adenocarcinomas of never-smokers from East Asia, KRAS mutations 3.8 times more common in those from North America and Europe than in those from East Asia, and a mutation pattern of unknown cause, called SBS40a, was enriched in tumors with EGFR mutations 72. Patients from regions with more air pollution carried more mutations of most types, including a 3.9-fold increase in SBS4, a pattern previously linked to tobacco smoking, with more mutations at higher pollution levels, while secondhand smoke showed no such link 72. In people, both studies are observational, so pollution may promote mutations already present, add new ones, or both; neither proves cause 72,91.
| Population | Share with an EGFR mutation | Source |
|---|---|---|
| 617 non-small-cell lung cancers, four countries, 2005 | 21% overall; never-smokers 51%, ever-smokers 10%; East Asian 30%, others 8%; women 42%, men 14% | 35 |
| 1,450 advanced adenocarcinomas, seven Asian regions, 2014 | 51.4% overall; women 61.1%, men 44.0%; never-smokers 60.7%; >50 pack-years 31.4%; India 22.2% | 34 |
| 33,162 adenocarcinomas, 151 studies, 2015 | Asia-Pacific 47% (20% to 76%); Oceania 12% | 90 |
| Histologically normal lung (not tumor), 295 people, 2023 | EGFR drivers in 18% of samples (KRAS in 53%) | 91 |
The words, defined
- Never-smoker
- In these studies, someone who smoked fewer than 100 cigarettes in a lifetime.
- Pack-year
- One pack of cigarettes a day for one year, or its equivalent.
- PM2.5
- Airborne particles 2.5 micrometers across or smaller, small enough to reach the alveoli.
Resistance, and the drug built to beat it
The responses to gefitinib and erlotinib were real but temporary 52,53. In 2005 a Boston group reported a man who had been in complete remission on gefitinib for two years and then relapsed; his tumor now carried a second mutation, threonine replaced by methionine at position 790, which modeling and biochemistry showed made the receptor resistant to the drug 52. A Memorial Sloan Kettering series found the same T790M mutation in two of five patients with acquired resistance, and not in the untreated tumors they examined, and pointed out that an analogous mutation had been seen in resistance to another kinase inhibitor, imatinib, the pill for chronic myeloid leukemia 53. In the largest series, 155 patients with lung adenocarcinoma rebiopsied after resistance to gefitinib or erlotinib, T790M was found in 63%, amplification of MET, another receptor tyrosine kinase, in 4 of 75 tested (5%), and transformation to small-cell lung cancer, a different and faster-growing type, in 3% 92. Earlier, smaller series had put MET amplification at 4 of 18 (22%), with MET driving the signal through HER3, and small-cell transformation at 5 of 37 (14%) 78,93. And T790M is not only acquired: in one family with several lung cancers it was inherited through the germline, the line of egg and sperm, and so present in every cell, and four of six tumors analyzed carried a second, activating EGFR mutation as well 54.
Osimertinib was designed for that problem: an oral, third-generation inhibitor, coming after the first-generation gefitinib and erlotinib and the second-generation afatinib and dacomitinib, irreversible, and selective for both the sensitizing mutations and T790M 13,17,18. In AURA3, 419 patients whose tumors had acquired T790M were given osimertinib or platinum-pemetrexed chemotherapy: median progression-free survival was 10.1 against 4.4 months (hazard ratio 0.30), 71% against 31% responded, the benefit held in the 144 with brain metastases, and severe adverse events were half as common, 23% against 47% 59.
The next step was to use it first 13. In FLAURA, 556 untreated patients were given osimertinib or gefitinib or erlotinib: median progression-free survival was 18.9 against 10.2 months (hazard ratio 0.46) 13, and median overall survival 38.6 against 31.8 months (hazard ratio 0.80, with a confidence interval reaching 1.00 and P = 0.046) 62. That survival gain is statistically significant but modest: the confidence interval reaches 1.00, so the data are also compatible with almost no gain 62. Osimertinib alone nonetheless became the comparator against which the next trials were run 14,94.
Then earlier still 63,68. In ADAURA, 682 patients whose stage IB to IIIA tumors had been completely removed took osimertinib or placebo for three years; at 24 months, 90% against 44% of those with stage II to IIIA disease were alive without recurrence 63, and at five years 85% against 73% were alive (hazard ratio 0.49), and 88% against 78% across all stages 64. In LAURA, 216 patients with unresectable stage III disease that had not progressed after chemoradiation took osimertinib or placebo: median progression-free survival was 39.1 against 5.6 months (hazard ratio 0.16) 68. Survival in LAURA was still immature at the first report, with a hazard ratio of 0.81 and a confidence interval from 0.42 to 1.56, and severe adverse events were nearly three times as common on the drug, 35% against 12%, with radiation pneumonitis in 48% against 38% 68. AURA3, FLAURA, ADAURA and LAURA were all funded by AstraZeneca 13,59,63,68.
Neither ADAURA nor LAURA tested giving osimertinib only when the cancer came back instead of at once; both compared it with placebo 63,68. That question matters: in a 2025 retrospective real-world study, drawn from the records of ordinary care rather than a trial, of 172 patients with unresectable stage III disease, 78% of whom were given chemoradiation alone, progression in that group came at a median of 6.7 months but median survival was 68.6 months; of the 115 patients who received further treatment, 86 were given an EGFR pill, which the authors suggest may explain the long survival, and two authors were AstraZeneca employees 95. In 2025, NeoADAURA moved the drug before surgery: among 358 patients with resectable stage II to IIIB disease, a major pathologic response, meaning that little living cancer remained in the tissue removed at surgery, occurred in 26% given osimertinib with chemotherapy and 25% given osimertinib alone, against 2% given chemotherapy with placebo; event-free survival data were only 15% mature, and several authors were AstraZeneca employees 70.
Resistance came again 58. In 2015 sequencing of tumor DNA in the blood of patients whose cancers had escaped osimertinib, then called AZD9291, found a new mutation, cysteine replaced by serine at position 797, in 6 of 15; 5 kept T790M without it, and 4 lost T790M altogether while keeping the original mutation 58. There is no single resistance mechanism after osimertinib 58; a 2026 analysis found, for example, that among 113 patients sequenced again at resistance, those whose tumors had carried extra copies of EGFR at the start more often acquired changes in another receptor, MET, 29% against 12% 96.
| Trial | Setting | Comparison | Main result | Survival |
|---|---|---|---|---|
| AURA3, 2017 | T790M after a first EGFR pill, 419 patients | Osimertinib vs platinum-pemetrexed | Progression-free 10.1 vs 4.4 months, HR 0.30 | Not the primary end point |
| FLAURA, 2018 and 2020 | Untreated advanced, 556 | Osimertinib vs gefitinib or erlotinib | Progression-free 18.9 vs 10.2 months, HR 0.46 | 38.6 vs 31.8 months, HR 0.80 |
| ADAURA, 2020 and 2023 | Resected stage IB to IIIA, 682 | Osimertinib vs placebo for 3 years | Disease-free at 2 years 90% vs 44% (stage II to IIIA) | 5-year 88% vs 78%, HR 0.49 |
| LAURA, 2024 | Unresectable stage III after chemoradiation, 216 | Osimertinib vs placebo | Progression-free 39.1 vs 5.6 months, HR 0.16 | Immature, HR 0.81 (0.42 to 1.56) |
The words, defined
- T790M
- Replacement of threonine by methionine at position 790 of the receptor; the commonest cause of resistance to the first EGFR pills.
- C797S
- Replacement of cysteine by serine at position 797; a cause of resistance to osimertinib.
- Irreversible inhibitor
- A drug that forms a permanent chemical bond with its target, rather than binding and letting go.
- Adjuvant treatment
- Treatment given after surgery to reduce the chance that cancer returns.
- Chemoradiation
- Chemotherapy and radiation given together.
- Confidence interval
- The range of values the data are compatible with; a hazard-ratio interval that reaches 1.00 includes no effect at all.
- P value
- How surprising a result would be if the treatment truly did nothing; below 0.05 is conventionally called significant.
- Disease-free survival
- Time after surgery until the cancer returns or the patient dies.
- Event-free survival
- Time until any of a trial's predefined events, such as progression, recurrence or death, occurs.
- Retrospective study
- A study that looks back at patients already treated, or at samples already stored, rather than following patients forward under a plan set in advance.
- End point
- The outcome a trial measures to judge a treatment; the primary end point is the one the trial was designed around.
- Stage
- How far a cancer has spread, from stage I, small and confined to where it began, to stage IV, spread to distant organs (metastatic).
- Resectable
- Able to be removed completely by surgery; a resected tumor is one that has been removed.
Beyond osimertinib alone: chemotherapy, a two-target antibody, and the rarer mutations
Two strategies have since beaten osimertinib alone as a first treatment, and both now have overall survival results 27,28. In FLAURA2, 557 patients took osimertinib with or without four cycles of platinum-pemetrexed chemotherapy followed by pemetrexed maintenance; progression-free survival improved (hazard ratio 0.62), with 57% against 41% free of progression at two years 94. The final survival analysis, published online in October 2025, gave a median of 47.5 against 37.6 months (hazard ratio 0.77, P = 0.02), at the cost of severe adverse events in 70% against 34% 27.
MARIPOSA tested amivantamab, an antibody with two arms, one binding EGFR and the other MET, a second growth factor receptor 16, given intravenously with lazertinib, an EGFR kinase-inhibitor pill, against osimertinib: of 1,074 patients enrolled, 429 were assigned to each of these two arms and 216 to lazertinib alone 14. Progression-free survival was 23.7 against 16.6 months (hazard ratio 0.70) 14. At the final survival analysis, after a median follow-up of 37.8 months, the hazard ratio for death was 0.75 (P = 0.005), with 60% against 51% alive at three years; severe adverse events occurred in 80% against 52%, chiefly skin problems, blood clots in the veins and reactions to the infusion 28. The trial was funded by Janssen, and many authors were Johnson & Johnson employees 28.
No trial has compared the two strategies with each other 27,28. Each beat osimertinib alone; each costs more toxicity than osimertinib alone; and each was funded by a company with a commercial stake, AstraZeneca for FLAURA2 and Janssen for MARIPOSA 27,28. The choice between them is a judgment about which side effects a patient would rather bear, chemotherapy's or the antibody's, and not a ranking the evidence can yet make 27,28.
The antibody's costs are being reduced. In PALOMA-3, 418 patients whose cancers had progressed on osimertinib and platinum chemotherapy received amivantamab with lazertinib, the antibody given either as an injection under the skin or as a drip into a vein: infusion reactions fell from 66% to 13% and blood clots in the veins from 14% to 9%, the first dose took a median of 4.8 minutes instead of 5 hours, and survival was longer with the injection (hazard ratio 0.62), although survival was an exploratory end point, one not used to judge the trial's success; the trial had Janssen employees among its authors 97. In the phase 2 COCOON trial, reported so far at a 2025 congress and in a commentary, a preventive regimen of an oral antibiotic (doxycycline or minocycline), a ceramide-based moisturizer, chlorhexidine nail care and the topical antibiotic clindamycin, given to patients starting amivantamab with lazertinib, halved grade 2 or worse skin reactions, 38.6% against 76.5% with reactive care 20.
Some tumors carry the sensitizing mutation and extra copies of the gene 96. In a 2026 retrospective study of 473 patients on first-line osimertinib, 17.1% had such amplification; they responded as often as the others, 88% against 83%, but their disease progressed sooner, at a median of 11.6 against 19 months, and they lived a shorter time, 34 against 40.1 months 96. That is an association in an observational cohort, a reason to study intensified treatment in that group rather than proof that it helps 96.
Exon 20 insertions, the third common type of mutation 35, behave differently: they are inherently resistant to the kinase inhibitors approved for the classic mutations 16. In PAPILLON, amivantamab with chemotherapy against chemotherapy alone in 308 untreated patients gave a median progression-free survival of 11.4 against 6.7 months (hazard ratio 0.40), with an interim survival hazard ratio of 0.67 that was not significant 65. An earlier exon 20 pill shows why first-line trials matter: in EXCLAIM-2, published in 2025, mobocertinib against platinum-pemetrexed in 354 untreated patients gave a median progression-free survival of 9.6 months in both arms (hazard ratio 1.04) and crossed the trial's futility boundary, with severe diarrhea in 20% against 1%; several authors, including statisticians, were Takeda employees 19. In WU-KONG28, published in May 2026, the oral drug sunvozertinib against carboplatin-pemetrexed in 324 untreated patients gave 10.3 against 7.5 months (hazard ratio 0.65) and a response rate of 58.9% against 31.1%, with severe adverse events in 75.5% against 56.7%; survival data were immature, and the trial was funded by Dizal Pharmaceuticals 15.
After osimertinib fails, randomized evidence now exists. In MARIPOSA-2, 657 patients whose cancers had progressed on osimertinib received amivantamab with carboplatin-pemetrexed, with or without lazertinib, or chemotherapy alone: median progression-free survival was 6.3 and 8.3 against 4.2 months (hazard ratios 0.48 and 0.44); Janssen staff were among the authors 66. In OptiTROP-Lung04, 376 patients in China whose cancers had progressed after EGFR pills received sacituzumab tirumotecan, an antibody-drug conjugate aimed at the surface protein TROP2, or platinum chemotherapy: median progression-free survival was 8.3 against 4.3 months (hazard ratio 0.49), and survival was longer (hazard ratio 0.60; 65.8% against 48.0% alive at 18 months), in a trial funded by the drug's maker, Sichuan Kelun-Biotech 71. By contrast, the HER3-directed conjugate patritumab deruxtecan improved progression-free survival in HERTHENA-Lung02 (hazard ratio 0.77) without a demonstrated survival benefit, according to a 2026 meta-analysis, a study that pools the results of earlier trials, so these conjugates are not interchangeable 98. Two trials published in The Lancet on 26 October 2026, both open-label and run only in China, added two more conjugates against platinum chemotherapy after EGFR pills. In PANKU-Lung01, 422 treated patients whose cancers had progressed on a third-generation pill received izalontamab brengitecan, the first conjugate aimed at both EGFR and HER3, or chemotherapy: median progression-free survival was 11.1 against 5.7 months (hazard ratio 0.40), at the cost of more severe side effects (grade 3 or worse in 79% against 62%), with survival reported only as an interim analysis, in a trial funded by the drug's maker, Baili-Bio 74. In HERON-Lung01, 498 patients received ruzaltatug rezetecan, a HER3-directed conjugate, or chemotherapy: at an interim analysis median progression-free survival was 8.3 against 5.4 months (hazard ratio 0.47), with severe side effects in 41% against 39%, in a trial funded by Jiangsu Hengrui 75. Whether either lengthens life, the test HERTHENA-Lung02 did not pass, is not yet known 74,75. Where MET is amplified, SACHI gave savolitinib, a pill aimed at MET, with osimertinib to 106 of 211 patients, all Asian, at 68 Chinese hospitals: median progression-free survival was 8.2 against 4.5 months on chemotherapy (hazard ratio 0.34), and the trial was funded by HUTCHMED and AstraZeneca 73. Immunotherapy has disappointed: in KEYNOTE-789, adding the immunotherapy antibody pembrolizumab to chemotherapy in 492 patients improved neither progression-free survival (5.6 against 5.5 months) nor survival (15.9 against 14.7 months) significantly, and several authors were Merck employees 69. In HARMONi-A, run only in China, ivonescimab, a bispecific antibody against PD-1 and VEGF, improved progression-free survival when added to chemotherapy (7.1 against 4.8 months, hazard ratio 0.46), with survival not yet mature, in a trial with authors from its maker, Akeso 99,100. In the ORCHARD platform study, a trial that tests several treatments under one protocol, 69 patients took osimertinib with datopotamab deruxtecan, another TROP2 conjugate: 43% and 36% responded at the two doses tested, and inflammation of the lungs occurred in 3% and 15% 101. That is a single-arm phase 2 result, and the conjugate is already approved on its own for EGFR-mutated lung cancer 101.
| First-line strategy | Trial | Progression-free survival | Overall survival | Severe adverse events |
|---|---|---|---|---|
| Osimertinib alone | FLAURA 13,62 | 18.9 months | 38.6 months | 34% (vs 45% on older pills) |
| Osimertinib plus platinum-pemetrexed | FLAURA2 27,94 | HR 0.62 vs osimertinib | 47.5 vs 37.6 months, HR 0.77 | 70% vs 34% |
| Amivantamab plus lazertinib | MARIPOSA 14,28 | 23.7 vs 16.6 months, HR 0.70 | HR 0.75; 3-year 60% vs 51% | 80% vs 52% |
The words, defined
- Bispecific antibody
- An engineered antibody with two different binding arms, here one for EGFR and one for MET.
- MET
- Another receptor tyrosine kinase, for hepatocyte growth factor; its amplification is one escape route from EGFR drugs.
- Exon 20 insertion
- A small addition of code in exon 20 of EGFR that switches the kinase on while leaving the drug pocket hard to reach.
- TROP2
- A surface protein common on carcinoma cells, used as an address for antibody-drug conjugates.
- PD-1
- Programmed cell death protein 1, a brake on T cells that tumors exploit; checkpoint-inhibitor drugs block it.
- VEGF
- Vascular endothelial growth factor, the signal that makes new blood vessels grow.
- Grade (of a side effect)
- A severity scale from 1, mild, to 5, death; grade 2 is moderate and grade 3 severe.
How the receptor is tested, in tissue and in blood
Because the decision turns on the gene's sequence, EGFR testing in lung cancer means reading tumor DNA 42. The 2018 guideline of the College of American Pathologists, the International Association for the Study of Lung Cancer and the Association for Molecular Pathology recommends against staining tumors for the EGFR protein to choose treatment, allows small cytology samples to be tested, asks for assays that can detect T790M when it makes up as little as 5% of the DNA, and endorses testing circulating cell-free DNA to rule a mutation in when tissue is limited or hard to obtain 42. That guideline predates the trials that moved osimertinib into resected, stage III and pre-surgical disease, all of which enrolled only patients whose tumors carried a sensitizing mutation, so the test now matters at those stages too 64,68,70.
Liquid biopsy, the reading of tumor DNA fragments shed into the blood, entered clinical practice through this receptor: the first liquid-biopsy test approved by the FDA detected EGFR mutations in plasma, and a 2017 commentary summarized many studies showing high agreement between tissue and plasma 102,103. When gefitinib was approved again in 2015, a tissue test for the mutations was approved alongside it as its companion diagnostic, a test required before a particular drug is given 26. By 2021 the International Association for the Study of Lung Cancer described plasma circulating tumor DNA as the most extensively studied alternative to tissue testing, and debated whether to test plasma first or tissue first 103. Blood also tracks resistance: C797S was found by sequencing plasma 58.
The limit is asymmetry 42. A mutation found in plasma can be acted on, but the guideline endorses plasma only to rule a mutation in, so a negative plasma result still calls for tissue 42. Tissue has limits of its own, which the 2021 consensus describes as considerable 103.
The words, defined
- Liquid biopsy
- Testing a blood sample for fragments of tumor DNA rather than taking tissue.
- Cell-free DNA
- Short pieces of DNA floating in plasma, released by dying cells; in cancer, part of it comes from the tumor.
- Immunohistochemistry
- Staining a tissue slice with an antibody to show where and how much of a protein is present.
- Companion diagnostic
- A test that must be done before a particular drug is given, to find the patients it is meant for.
Colorectal cancer: the receptor matters only when the gene below it is normal
In colorectal cancer the drugs aimed at EGFR are antibodies, cetuximab and panitumumab, that bind the receptor from outside the cell 2. Cetuximab is a chimeric antibody, part mouse and part human 104; panitumumab is fully human 30. In 2004 the BOND trial gave cetuximab, with or without irinotecan, to 329 patients whose cancers had progressed on irinotecan: 22.9% responded with the combination and 10.8% with cetuximab alone 105. Most patients, in other words, did not respond 105. Nor did the amount of receptor pick the responders. In 2005 a Memorial Sloan Kettering review found 16 patients with chemotherapy-resistant colorectal cancer whose tumors showed no EGFR on staining but who had been given cetuximab outside a trial: 4 had major responses, 25%, and the authors concluded that staining should not be used to include or exclude patients 106.
What decided it turned out to be the gene below the receptor 29,30. In 2008 a retrospective analysis of a panitumumab trial, led by an Amgen scientist, found KRAS mutations in 43% of 427 tumors; the drug's effect on progression-free survival was confined to tumors without them (hazard ratio 0.45 against 0.99), and 17% of wild-type tumors responded against none of the mutant ones 30. The same year a retrospective analysis of tumors from 394 of the 572 patients in CO.17, a randomized trial of cetuximab against supportive care alone, found that cetuximab improved median survival from 4.8 to 9.5 months in KRAS wild-type tumors (hazard ratio 0.55), and not at all in mutant ones (hazard ratio 0.98); KRAS status made no difference to survival on supportive care alone, so it predicted the drug's effect rather than the patient's fate 29. KRAS sits below EGFR in the signaling chain, and when it is stuck on, blocking the receptor above it cannot turn the chain off 2,29.
In 2013 the restriction widened 43. A reanalysis of the PRIME trial found that 17% of tumors without the classic KRAS exon 2 mutations carried other KRAS or NRAS mutations, NRAS being a close relative of KRAS, and those patients also did worse with panitumumab; in the 512 without any RAS mutation, median survival was 26.0 against 20.2 months (hazard ratio 0.78) 43. All-RAS testing became the entry ticket 43,107.
Where the tumor sits matters too. In a pooled retrospective analysis of six randomized trials, in which tumor side was known for 2,159 patients with RAS wild-type disease, antibodies against EGFR added to chemotherapy improved survival in left-sided tumors, those arising in the last part of the colon or in the rectum (hazard ratio 0.75), but not significantly in right-sided tumors (hazard ratio 1.12); the authors cautioned that the analysis was retrospective 108. The Japanese PARADIGM trial, which tested left-sided tumors first, reported in 2023: among 823 patients with RAS wild-type disease, chemotherapy with panitumumab or with bevacizumab, an antibody against blood-vessel growth, gave median survival of 37.9 against 34.3 months in left-sided tumors (hazard ratio 0.82) and 36.2 against 31.3 months across the whole trial (hazard ratio 0.84), with no difference in progression-free survival in left-sided tumors (13.1 against 11.9 months, hazard ratio 1.00), and acneiform rash in 74.8% against 3.2% 32. Two authors were employees of Takeda 32.
The receptor also explains a failure elsewhere 44. Vemurafenib, which blocks the mutant BRAF protein and works well in melanoma, barely works in colon cancers with the same mutation; in 2012 a Netherlands Cancer Institute group showed that blocking BRAF in colon cancer cells rapidly reactivates EGFR, which keeps the cells growing, whereas melanoma cells make little EGFR 44. In the 2025 BREAKWATER trial in untreated BRAF V600E colorectal cancer, the BRAF inhibitor encorafenib with cetuximab and chemotherapy gave a median progression-free survival of 12.8 against 7.1 months and, at an interim analysis, median survival of 30.3 against 15.1 months (hazard ratio 0.49) 45. The trial was funded by Pfizer and others, with Pfizer employees among the authors 45.
The rule that antibodies against EGFR are wasted on KRAS-mutant tumors has itself been partly overturned. KRAS G12C, glycine replaced by cysteine at position 12, a mutation in about 3 to 4% of patients with metastatic colorectal cancer, can now be blocked directly, but such pills alone have had only modest effect; in CodeBreaK 300, 160 patients whose cancers had progressed on chemotherapy received sotorasib, a KRAS G12C inhibitor, at one of two doses with panitumumab, or standard care, and median progression-free survival was 5.6 months at the higher dose against 2.2 months (hazard ratio 0.49), with responses in 26.4% against 0% 67. Skin toxicity and low magnesium, the receptor's signatures, were the commonest side effects; survival data were still maturing, and the trial was funded by Amgen, with Amgen employees among the authors 67.
The words, defined
- Monoclonal antibody
- A laboratory-made antibody of a single type that binds one specific target.
- Chimeric antibody
- An antibody whose binding regions come from a mouse and the rest from a human antibody.
- Wild-type
- The normal, unmutated form of a gene.
- BRAF V600E
- A mutation in BRAF, a kinase just below RAS, that replaces valine with glutamate at position 600 and leaves BRAF switched on.
Head and neck cancer: a partner for radiation that lost to cisplatin
In 2006 an international trial gave 424 patients with locally advanced squamous-cell cancer of the head and neck high-dose radiation alone or radiation with weekly cetuximab: control of the cancer in the head and neck lasted a median 24.4 against 14.9 months, and median survival was 49.0 against 29.3 months (hazard ratio 0.74), without more severe mouth inflammation, although acneiform rash and infusion reactions were more common 55. At five years, 45.6% against 36.4% were alive 41. The comparison was with radiation alone, not with radiation plus cisplatin, the usual chemotherapy partner, and the trial was funded by ImClone, Merck KGaA and Bristol-Myers Squibb 41,55.
The first test of cetuximab next to cisplatin came in RTOG 0522, published in 2014: 891 patients with stage III or IV head and neck cancer received radiation and cisplatin with or without cetuximab, and adding the antibody did not improve outcome, with three-year progression-free survival 61.2% without cetuximab and 58.9% with it, and three-year survival 72.9% and 75.8%, while severe inflammation of the mouth lining from radiation rose from 33.3% to 43.2% and radiation more often had to be interrupted, 26.9% against 15.1% 57. The amount of EGFR in the tumor did not distinguish outcome 57.
A different disease then grew within the old one 60. Cancer of the oropharynx caused by human papillomavirus, HPV, affects younger patients, is rising, and has high survival when treated with radiation and cisplatin, so cetuximab was proposed as a gentler replacement 60,61. Two trials tested it and published in late 2018 60,61. In De-ESCALaTE, 334 low-risk patients in Ireland, the Netherlands and the United Kingdom received radiation with cisplatin or with cetuximab: severe toxicity was identical, 4.8 events per patient in both arms, while two-year survival was 97.5% with cisplatin against 89.4% with cetuximab (hazard ratio 5.0) and two-year recurrence was 6.0% against 16.1% 60. In RTOG 1016, 849 patients in the United States and Canada: cetuximab failed to show it was no worse, with five-year survival 77.9% against 84.6%, progression-free survival 67.3% against 78.4%, cancer returning in the head and neck in 17.3% against 9.9%, and similar toxicity 61.
The belief that an antibody against EGFR would be the kinder partner for radiation in HPV-positive cancer was reversed on both counts: it was no kinder, and it controlled the cancer less well 60,61. Radiation with cisplatin remains the standard for patients who can tolerate cisplatin 60,61. For patients who cannot take cisplatin, the question is different. In NRG-HN004, published in 2024, 186 such patients in North America were randomized to radiation with durvalumab, an immunotherapy antibody, or with cetuximab; the trial was stopped after an interim futility analysis, and in a post hoc extended follow-up, two-year progression-free survival was 50.6% with durvalumab against 63.7% with cetuximab (hazard ratio 1.33); the authors concluded that durvalumab did not improve outcomes and that the standard for these patients is still to be defined, and the trial was funded by the US National Cancer Institute and AstraZeneca 109.
The words, defined
- Oropharynx
- The middle part of the throat, including the tonsils and base of the tongue.
- Non-inferiority trial
- A trial designed to show that a new treatment is not worse than the standard by more than a preset margin.
- Locoregional control
- Keeping the cancer from growing back at its original site and in the nearby lymph nodes.
The rash, the magnesium and a sugar on the antibody
The commonest cost of blocking EGFR is a papulopustular rash, pimple-like bumps and pus-filled spots on the face and upper torso, which comes on in a dose-dependent way 40. It is often called acneiform because it looks like acne, but it is a direct consequence of blocking a receptor the skin depends on, and the child born without a working receptor had a similar rash 31,79. A 2005 review found a consistent association between rash and response, and rash and survival, with cetuximab and erlotinib, and a less consistent one with gefitinib, and said the reason was unclear 40. In the cetuximab and radiation trial, patients with a rash of grade 2 or worse lived longer than those with none or a mild one (hazard ratio 0.49) 41. Those are associations within treated patients; they do not mean that a rash causes benefit, or that its absence means the drug is failing 40.
The rash can be blunted without stopping treatment 110. In the STEPP trial, 95 colorectal cancer patients on panitumumab were randomized to start moisturizer, sunscreen, a topical steroid and the antibiotic doxycycline before any rash appeared, or to treat the rash once it came; grade 2 or worse skin toxicity over six weeks fell from 62% to 29%, and quality of life was less impaired 110.
Magnesium loss is the hidden cost 33. Serum magnesium fell in 97% of colorectal cancer patients on antibodies against the receptor in a prospective study, through a defect in reabsorption by the kidney 33, the same pathway that a rare inherited EGF mutation disables 76. Diarrhea is common with the pills, 46.6% on gefitinib in IPASS 25, and the newer combinations add their own costs: with amivantamab, infusion reactions, inflammation around the nails and blood clots 16,28. Gefitinib's approval summary recorded interstitial lung disease in about 1% of patients worldwide and 2% in Japanese experience, a third of cases fatal 21.
One reaction has nothing to do with the receptor at all 104. In 2008 a Vanderbilt-led study investigated why hypersensitivity reactions to cetuximab were unusually common in some areas of the United States, with patients drawn mainly from Tennessee, Arkansas and North Carolina: 25 of 76 treated patients had reacted, and 17 of those 25 already had IgE antibodies against the drug before the first dose, against 1 of 51 who did not react 104. The IgE recognized a sugar, galactose-alpha-1,3-galactose, attached to the antibody's Fab portion, the arm that binds its target, and was present in 20.8% of control subjects in Tennessee, 6.1% in northern California and 0.6% in Boston 104. The reaction, in other words, was largely predictable before treatment began, from an antibody the patient already carried, which was far more common in Tennessee than in Boston 104. The reason for the map emerged three years later: in a 2011 study, IgE to alpha-gal rose 20-fold or more after tick bites in three people followed prospectively, its level tracked with histories of tick bites, and it was common where the lone star tick, Amblyomma americanum, is common; the same antibody causes a delayed allergy to red meat, and the authors concluded that tick bites are a cause, possibly the only cause, of this IgE in that region 111.
The words, defined
- Papulopustular
- Made of small raised bumps (papules) and pus-filled spots (pustules).
- IgE
- The class of antibody that triggers allergic reactions, including anaphylaxis.
- Alpha-gal
- Galactose-alpha-1,3-galactose, the sugar on cetuximab that pre-existing IgE recognized in the patients who reacted.
- Interstitial lung disease
- Inflammation and scarring of the tissue between the air sacs of the lung.
What was believed and is not, and what is still open
The first belief to fall was that the amount of receptor would decide who benefits 21,89. Tumors that made more EGFR, or had more copies of the gene, seemed the natural targets; in lung cancer the deciding feature turned out to be a mutation in the kinase, high copy number without a mutation went with shorter progression-free survival on gefitinib than on chemotherapy in a post hoc analysis, and the guideline now advises against protein staining for this purpose 42,89. In glioblastoma, where the receptor is amplified and rearranged, erlotinib showed insufficient activity in a randomized phase 2 trial, a randomized trial of an EGFRvIII vaccine did not prolong life, and an EGFR-directed antibody-drug conjugate showed no survival gain at the interim analysis of its phase 3 trial 38,82,83,84,85.
The second was that patients could be chosen by how they looked 25. Being East Asian, a never-smoker or light former smoker and having adenocarcinoma did enrich for the mutation, but in IPASS, which chose patients on exactly those features, those whose tumors lacked it progressed far sooner on gefitinib than on chemotherapy (hazard ratio for progression-free survival 2.85) 25, and in the largest Asian survey sex stopped mattering once smoking was accounted for 34.
The third was that antibodies against EGFR would help colorectal cancer broadly; they help only tumors without RAS mutations, first shown for KRAS exon 2 in 2008 and widened to all RAS in 2013 29,30,43. The fourth was that cetuximab would be the gentler partner for radiation in HPV-positive throat cancer; it was not gentler and it was less effective 60,61.
Others have fallen since. The amount of receptor failed in colorectal cancer too: tumors with no EGFR on staining responded to cetuximab 106, and in head and neck cancer the amount of EGFR did not distinguish outcome, while adding cetuximab to cisplatin and radiation did not improve it 57. T790M, first found only in tumors that had escaped treatment, can also be inherited 53,54. An exon 20 pill failed against chemotherapy in its first-line trial 19. Immunotherapy added nothing significant after EGFR pills in KEYNOTE-789 69. And KRAS-mutant colorectal cancer, once the clearest case for withholding antibodies against EGFR, now has a trial in which one, given alongside a KRAS G12C inhibitor, beat standard care 67.
Several questions remain open as of October 2026. FLAURA2 and MARIPOSA both showed that adding more at the start prolongs life compared with osimertinib alone followed by whatever came next, but the two combinations have not been compared with each other, and which patients need the extra toxicity is unsettled 27,28. Whether osimertinib after chemoradiation prolongs life awaits mature LAURA data, and a real-world study in which patients given chemoradiation alone lived a median of 68.6 months, most of those treated again receiving EGFR pills, shows why that comparison is hard to win 68,95. Whether NeoADAURA's better pathology at surgery becomes longer survival is not yet known 70, and the strongest survival result after EGFR pills fail, for sacituzumab tirumotecan, comes from a trial run only in China 71. Whether air pollution causes EGFR-mutant lung cancer in people, by adding mutations, promoting existing ones or both, still rests on observational human data and mouse experiments 72,91. And whether delivering EGFR-directed cells or toxins straight into the brain can finally change the course of glioblastoma is, so far, a question asked of very small uncontrolled studies 86,87,88.
Where it connects
In the Atlas
Topics on the map
On the map
A star in Oncogenes, one of 3. The receptor for epidermal growth factor: mutated in a subset of lung cancers that answer to targeted pills, and the reason a KRAS test decides who gets cetuximab
Sources
112 sources, numbered as they are cited. Every one was checked against PubMed or its publisher before it was cited here; the note under each says what it shows and what it does not.
- 1Singh B, Carpenter G, Coffey RJ. EGF receptor ligands: recent advances.doi:10.12688/f1000research.9025.1 · PMID 27635238
Review. Seven ligands activate EGFR (also called ERBB1 and HER1): EGF, TGF-alpha, HB-EGF and betacellulin, thought to bind with high affinity, and amphiregulin, epiregulin and epigen with low affinity.
- 2Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer.doi:10.1016/j.phrs.2013.11.002 · PMID 24269963
Review. Four family members (ErbB1 to 4); the receptor's parts (glycosylated outer domain, single membrane-crossing segment, juxtamembrane segment, kinase domain, tail); ligand binding exposes a domain II dimerization arm; the back-to-back dimer; the asymmetric kinase dimer; signaling through PI3K-AKT, RAS-RAF-MEK-ERK and phospholipase C gamma; HER2 has no ligand and HER3 is kinase-impaired, yet the HER2-HER3 pair is the strongest signaling complex.
- 3Inker LA, Eneanya ND, Coresh J, Tighiouart H, et al. New creatinine- and cystatin C-based equations to estimate GFR without race.doi:10.1056/NEJMoa2102953 · PMID 34554658
Cited only to define eGFR on a kidney report: an estimated glomerular filtration rate calculated from serum creatinine, with or without cystatin C, plus age and sex. The 2021 equations removed race. It has nothing to do with the receptor.
- 4Fromhage G, Obermayr E, Bednarz-Knoll N, Van Gorp T, et al. Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long-term survival in ovarian cancer-A study from the OVCAD consortium.doi:10.1002/ijc.34976 · PMID 38709956
The title places the HERVK retrotransposons it studies at 7p11.2 in relation to EGFR; the abstract does not itself state the EGFR locus. Its ovarian cancer findings are not used here. Cross-check against NCBI Gene ID 1956 (EGFR, 7p11.2) before publishing.
- 5Ullrich A, Coussens L, Hayflick JS, Dull TJ, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.doi:10.1038/309418a0 · PMID 6328312
The complete 1,210-amino-acid precursor sequence from placental and A431 cDNA; one 23-amino-acid transmembrane segment; close similarity of the transmembrane and cytoplasmic parts to the v-erbB product; the gene amplified and apparently rearranged in A431 cells, which make a truncated 2.8-kilobase message encoding only the outer domain.
- 6Ogiso H, Ishitani R, Nureki O, Fukai S, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.doi:10.1016/s0092-8674(02)00963-7 · PMID 12297050
A 2:2 complex of EGF with the receptor's outer region at 3.3 angstrom resolution: domains I to III form a C shape, EGF docks between I and III, and a beta-hairpin arm of domain II holds the partner receptor, so the receptors, not the ligands, make the contact. Confirmed by mutagenesis.
- 7Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.doi:10.1016/j.cell.2006.05.013 · PMID 16777603
The kinase is autoinhibited on its own, in a conformation like Src and the cyclin-dependent kinases; it is switched on by raising its local concentration or by mutating a leucine in its activation loop, without needing that loop phosphorylated. Activation comes from an asymmetric dimer in which the C-terminal lobe of one kinase acts as cyclin does for a CDK. Crystallography and cell experiments, not patients.
- 8Cohen S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal.PMID 13880319
The founding paper. PubMed holds no abstract and no DOI for it; the claim used here is the one in its title: a protein from the mouse submaxillary (salivary) gland that made newborn mice open their eyelids and erupt their incisors early.
- 9Carpenter G, Lembach KJ, Morrison MM, Cohen S. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts.PMID 1126952
Radioiodinated EGF bound human fibroblasts specifically and saturably, about 100,000 molecules per cell, with an apparent dissociation constant of 2.7 to 4.3 x 10^-10 M; cells from human, mouse, rat and chick all had the receptor. In vitro; PubMed lists no DOI for this paper.
- 10Carpenter G, King L, Cohen S. Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro.doi:10.1038/276409a0 · PMID 309559
The first evidence that EGF switches on an enzyme that adds phosphate to proteins, in isolated membranes. No abstract in PubMed; cited for its title claim.
- 11Ushiro H, Cohen S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.PMID 6157683
In membranes from A-431 human epidermoid carcinoma cells, EGF-stimulated phosphorylation landed on tyrosine, with only traces, if any, on serine or threonine; the receptor-kinase complex purified by EGF affinity chromatography phosphorylated tyrosine itself. In vitro. PubMed lists no DOI; its PII is S0021-9258(18)43497-7, and the JBC archive DOI that would follow it could not be resolved from this environment.
- 12Downward J, Yarden Y, Mayes E, Scrace G, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences.doi:10.1038/307521a0 · PMID 6320011
Six peptides from the purified human receptor, 83 amino acids in all, of which 74 matched the predicted v-erbB protein of avian erythroblastosis virus. The authors proposed that the virus had captured a truncated receptor lacking the outer EGF-binding domain. A sequence comparison; the transformation mechanism was a hypothesis.
- 13Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.doi:10.1056/NEJMoa1713137 · PMID 29151359
FLAURA: 556 patients with exon 19 deletion or L858R; osimertinib, an oral third-generation irreversible inhibitor selective for sensitizing and T790M mutations, versus gefitinib or erlotinib: progression-free survival 18.9 versus 10.2 months (hazard ratio 0.46); response 80% versus 76%; grade 3 or worse adverse events 34% versus 45%. Funded by AstraZeneca.
- 14Cho BC, Lu S, Felip E, Spira AI, et al. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa2403614 · PMID 38924756
MARIPOSA: 1,074 patients (429 amivantamab-lazertinib, 429 osimertinib, 216 lazertinib alone); progression-free survival 23.7 versus 16.6 months (hazard ratio 0.70); response 86% versus 85%; all drugs stopped for treatment-related adverse events in 10% versus 3%. Funded by Janssen.
- 15Zhou C, Greillier L, Liu G, John T, et al. First-line sunvozertinib in NSCLC with EGFR exon 20 insertion mutations.doi:10.1056/NEJMoa2604461 · PMID 42212913
WU-KONG28: 324 patients; oral sunvozertinib versus carboplatin-pemetrexed: progression-free survival 10.3 versus 7.5 months (hazard ratio 0.65); response 58.9% versus 31.1%; survival immature; grade 3 or worse adverse events 75.5% versus 56.7%, chiefly creatine kinase rises, diarrhea and anemia. Funded by Dizal Pharmaceuticals; a Dizal employee is among the authors.
- 16Park K, Haura EB, Leighl NB, Mitchell P, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.doi:10.1200/JCO.21.00662 · PMID 34339292
Describes amivantamab as an EGFR-MET bispecific antibody that binds both receptors' outer domains, bypassing the kinase-inhibitor binding site; exon 20 insertions are inherently resistant to approved kinase inhibitors. In 81 patients, 40% responded; rash in 86%, infusion reactions in 66%. Single-arm; Janssen authors.
- 17Sequist LV, Yang JC, Yamamoto N, O'Byrne K, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.doi:10.1200/JCO.2012.44.2806 · PMID 23816960
LUX-Lung 3: 345 patients; afatinib, an irreversible blocker of EGFR, HER2 and ErbB4, versus cisplatin-pemetrexed; progression-free survival 11.1 versus 6.9 months (hazard ratio 0.58). Three authors were Boehringer Ingelheim employees.
- 18Wu YL, Cheng Y, Zhou X, Lee KH, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.doi:10.1016/S1470-2045(17)30608-3 · PMID 28958502
452 patients; dacomitinib, a second-generation irreversible inhibitor, versus the reversible gefitinib; progression-free survival 14.7 versus 9.2 months (hazard ratio 0.59); grade 3-4 acneiform dermatitis 14% versus none. Funded by SFJ Pharmaceuticals Group and Pfizer, with employees of both among the authors.
- 19Jänne PA, Wang BC, Cho BC, Zhao J, et al. First-line mobocertinib versus platinum-based chemotherapy in patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer in the phase III EXCLAIM-2 trial.doi:10.1200/JCO-24-01269 · PMID 39879577
354 patients; median progression-free survival 9.6 months in both arms (hazard ratio 1.04); crossed the prespecified futility boundary; grade 3 or worse diarrhea 20% versus 1%. Several authors, including statisticians, were Takeda employees.
- 20Tiwari B, Koirala A. Early success of the COCOON trial: preventing dermatologic adverse events in first-line EGFR-mutant NSCLC.doi:10.18632/oncoscience.648 · PMID 41859193
Commentary on interim results of the phase 2 COCOON trial presented at the 2025 European Lung Cancer Congress: oral doxycycline or minocycline, ceramide-based moisturizer, chlorhexidine nail care and topical clindamycin cut grade 2 or worse skin events from 76.5% to 38.6%. Secondary source; replace with the primary COCOON report once it is indexed.
- 21Cohen MH, Williams GA, Sridhara R, Chen G, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets.doi:10.1158/1078-0432.ccr-03-0564 · PMID 14977817
Written by FDA reviewers. Accelerated approval of AstraZeneca's gefitinib on 5 May 2003, after platinum and docetaxel, on a 10.6% response rate (15 of 142), responses more frequent in women and nonsmokers; two trials adding gefitinib to chemotherapy (1,093 and 1,037 patients) showed no benefit; interstitial lung disease in about 1% worldwide (2% in Japanese postmarketing experience), about a third fatal. Notes that gefitinib, called selective, inhibits other tyrosine kinases at clinically reached concentrations, that no clinical study linked EGFR expression to response, and that no controlled trial had yet shown clinical benefit.
- 22Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.doi:10.1056/NEJMoa040938 · PMID 15118073
About 10% of patients had rapid, often dramatic responses. Kinase-domain mutations in 8 of 9 responders and 0 of 7 nonresponders; in 2 of 25 unexposed tumors (8%). Small deletions or substitutions near the ATP pocket; mutants were more active in response to EGF and more sensitive to gefitinib in cultured cells. Small, selected series.
- 23Paez JG, Jänne PA, Lee JC, Tracy S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.doi:10.1126/science.1099314 · PMID 15118125
Published the same day as Lynch. Somatic EGFR mutations in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States; present in US responders and in a hypersensitive cell line.
- 24Pao W, Miller V, Zakowski M, Doherty J, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.doi:10.1073/pnas.0405220101 · PMID 15329413
Exon 19 in-frame deletions and codon 858 point mutations in 7 of 10 gefitinib-sensitive and 5 of 7 erlotinib-sensitive tumors, none in 18 refractory ones; mutations in 7 of 15 adenocarcinomas from never-smokers (fewer than 100 cigarettes in a lifetime) versus 4 of 81 tumors from former or current smokers.
- 25Mok TS, Wu YL, Thongprasert S, Yang CH, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.doi:10.1056/NEJMoa0810699 · PMID 19692680
IPASS: 1,217 East Asian nonsmokers or former light smokers with adenocarcinoma. Overall progression-free survival favored gefitinib (hazard ratio 0.74); in 261 mutation-positive patients the hazard ratio was 0.48; in 176 mutation-negative patients it was 2.85, favoring chemotherapy. Rash or acne in 66.2% and diarrhea in 46.6% on gefitinib. The abstract does not name the funder.
- 26Kazandjian D, Blumenthal GM, Yuan W, He K, et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer.doi:10.1158/1078-0432.CCR-15-2266 · PMID 26980062
Written by FDA reviewers. Approval on 13 July 2015 for tumors with exon 19 deletions or L858R detected by an FDA-approved test, with the therascreen EGFR PCR kit approved as companion diagnostic; single-arm, open-label study of 106 untreated patients, response 50%; supported by a retrospective IPASS subset of 186 mutation-positive patients, progression-free survival hazard ratio 0.54.
- 27Jänne PA, Planchard D, Kobayashi K, Yang JC, et al. Survival with osimertinib plus chemotherapy in EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa2510308 · PMID 41104938
FLAURA2 final survival, published online 17 October 2025: median 47.5 versus 37.6 months (hazard ratio 0.77; 0.61 to 0.96; P = 0.02); grade 3 or worse adverse events 70% versus 34%; osimertinib stopped for adverse events in 12% versus 7%. Open-label. Funded by AstraZeneca.
- 28Yang JC, Lu S, Hayashi H, Felip E, et al. Overall survival with amivantamab-lazertinib in EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa2503001 · PMID 40923797
MARIPOSA final survival after a median 37.8 months: hazard ratio 0.75 (0.61 to 0.92; P = 0.005); 60% versus 51% alive at three years; grade 3 or worse adverse events 80% versus 52%, mainly skin, venous thromboembolism and infusion reactions. Funded by Janssen; many authors are Johnson & Johnson employees.
- 29Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer.doi:10.1056/NEJMoa0804385 · PMID 18946061
CO.17: tumors from 394 of 572 patients; 42.3% had KRAS exon 2 mutations. In wild-type tumors, cetuximab improved median survival 9.5 versus 4.8 months (hazard ratio 0.55); in mutant tumors there was no benefit (hazard ratio 0.98). KRAS status did not affect survival on supportive care alone, so it predicted drug benefit rather than prognosis.
- 30Amado RG, Wolf M, Peeters M, Van Cutsem E, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.doi:10.1200/JCO.2007.14.7116 · PMID 18316791
KRAS status in 427 of 463 trial patients; 43% mutated. Panitumumab's effect on progression-free survival was confined to wild-type tumors (hazard ratio 0.45 versus 0.99); responses 17% versus 0%. A retrospective analysis of a randomized trial; the first author was at Amgen.
- 31Campbell P, Morton PE, Takeichi T, Salam A, et al. Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR.doi:10.1038/jid.2014.164 · PMID 24691054
The first reported primary inherited EGFR defect: a homozygous p.Gly428Asp mutation in a boy with lifelong skin, bowel and lung inflammation; the skin rash resembled that of EGFR-inhibitor drugs; the mutant receptor could not be phosphorylated or signal; he died at 2.5 years of skin and chest infections and electrolyte imbalance. A single case report; two siblings with the same mutation were reported in 2015 [98].
- 32Watanabe J, Muro K, Shitara K, Yamazaki K, et al. Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial.doi:10.1001/jama.2023.4428 · PMID 37071094
PARADIGM: 823 Japanese patients with RAS wild-type disease; in left-sided tumors median survival 37.9 versus 34.3 months (hazard ratio 0.82); overall 36.2 versus 31.3 months; acneiform rash 74.8% versus 3.2%. Open-label; two authors are Takeda employees.
- 33Tejpar S, Piessevaux H, Claes K, Piront P, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study.doi:10.1016/S1470-2045(07)70108-0 · PMID 17466895
Prospective cohort of 98 patients on EGFR antibodies: 95 (97%) had falling serum magnesium; urine collections and magnesium load tests showed a renal reabsorption defect; 16 patients on chemotherapy alone did not show the fall.
- 34Shi Y, Au JS, Thongprasert S, Srinivasan S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).doi:10.1097/JTO.0000000000000033 · PMID 24419411
1,482 patients in seven Asian regions; 51.4% of 1,450 evaluable tumors mutated; 61.1% in women and 44.0% in men; 22.2% in India versus 47.2% to 64.2% elsewhere; 60.7% in never-smokers, falling to 31.4% above 50 pack-years; sex not significant after adjustment for smoking. AstraZeneca employees are among the authors.
- 35Shigematsu H, Lin L, Takahashi T, Nomura M, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.doi:10.1093/jnci/dji055 · PMID 15741570
617 non-small-cell lung cancers from Japan, Taiwan, the United States and Australia: mutations in 21%; 51% of never-smokers versus 10% of ever-smokers, 40% of adenocarcinomas versus 3% of other types, 30% of East Asian versus 8% of other patients, 42% of women versus 14% of men. None in matched normal lung. KRAS mutations (8%) never coexisted with EGFR mutations. Exon 19 deletions, exon 21 missense mutations and exon 20 insertions were the three common types.
- 36Libermann TA, Nusbaum HR, Razon N, Kris R, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.doi:10.1038/313144a0 · PMID 2981413
Four of ten primary glial brain tumors that expressed more receptor than normal also had amplified receptor genes; none of the other brain tumors examined did. Small series; the rearrangement was described as possible.
- 37Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas.doi:10.1073/pnas.87.21.8602 · PMID 2236070
In six primary glioblastomas, deletion-rearrangements of the amplified gene, different in extent from tumor to tumor, all produced the same transcript: exon 1 spliced to exon 8, losing the same 801 coding bases of exons 2 to 7 while keeping the reading frame. This is the variant later called EGFRvIII.
- 38Weller M, Butowski N, Tran DD, Recht LD, et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.doi:10.1016/S1470-2045(17)30517-X · PMID 28844499
745 patients; stopped for futility at interim analysis; in minimal residual disease, median survival 20.1 versus 20.0 months (hazard ratio 1.01). Funded by Celldex Therapeutics, several of whose employees are authors.
- 39Fiske WH, Tanksley J, Nam KT, Goldenring JR, et al. Efficacy of cetuximab in the treatment of Menetrier's disease.doi:10.1126/scitranslmed.3000320 · PMID 20368185
Single-arm trial in 9 patients with severe Ménétrier disease, a rare premalignant overgrowth of the stomach lining in which increased EGFR signaling is implicated: all 7 who completed a month improved in quality of life, parietal cell mass and acid output, and 4 later had near-complete histological remission. No control group.
- 40Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?doi:10.1200/JCO.2005.00.6916 · PMID 16051966
Review: a dose-dependent papulopustular rash on the face and upper torso; a consistent association between rash and response, and rash and survival, with cetuximab and erlotinib, less consistent with gefitinib; the cause of the association unclear.
- 41Bonner JA, Harari PM, Giralt J, Cohen RB, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.doi:10.1016/S1470-2045(09)70311-0 · PMID 19897418
Five-year survival 45.6% versus 36.4%. Among cetuximab-treated patients, those with grade 2 or worse acneiform rash lived longer than those with none or grade 1 (hazard ratio 0.49), an association within one arm. Funded by ImClone, Merck KGaA and Bristol-Myers Squibb.
- 42Lindeman NI, Cagle PT, Aisner DL, Arcila ME, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.doi:10.5858/arpa.2017-0388-CP · PMID 29355391
Pathology guideline: recommends against immunohistochemistry (protein staining) for EGFR testing, allows cytology samples, asks for assays sensitive to 5% for T790M, and endorses plasma cell-free DNA to rule in a targetable mutation when tissue is limited.
- 43Douillard JY, Oliner KS, Siena S, Tabernero J, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.doi:10.1056/NEJMoa1305275 · PMID 24024839
PRIME reanalysis: 108 (17%) of tumors without KRAS exon 2 mutations had other RAS mutations, and those patients did worse with panitumumab; in 512 with no RAS mutation, survival 26.0 versus 20.2 months (hazard ratio 0.78). Prospective-retrospective; funded by Amgen and others.
- 44Prahallad A, Sun C, Huang S, Di Nicolantonio F, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.doi:10.1038/nature10868 · PMID 22281684
Vemurafenib, effective in BRAF V600E melanoma, barely works in colon cancer with the same mutation because blocking BRAF rapidly reactivates EGFR; melanoma cells make little EGFR. Combined BRAF and EGFR blockade was synergistic in cells and mice. Laboratory evidence.
- 45Elez E, Yoshino T, Shen L, Lonardi S, et al. Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer.doi:10.1056/NEJMoa2501912 · PMID 40444708
BREAKWATER: in untreated BRAF V600E colorectal cancer, encorafenib plus cetuximab plus chemotherapy versus standard care: progression-free survival 12.8 versus 7.1 months (hazard ratio 0.53); interim survival 30.3 versus 15.1 months (hazard ratio 0.49). Open-label; funded by Pfizer, with Pfizer authors. Funded by Pfizer and others; four authors were Pfizer employees.
- 46Gregory H. Isolation and structure of urogastrone and its relationship to epidermal growth factor.doi:10.1038/257325a0 · PMID 1161035
No abstract in PubMed; cited for its title, and for its indexing under gastrointestinal hormones. Nothing about urogastrone's actions is claimed from it.
- 47Cohen S. Nobel lecture. Epidermal growth factor.doi:10.1007/BF01141022 · PMID 3555641
Cohen's own account, delivered as his Nobel lecture in 1986. No abstract in PubMed; cited for the fact of the lecture and the name the protein carried by then.
- 48Levi-Montalcini R. The nerve growth factor: thirty-five years later.doi:10.1007/BF01116861 · PMID 3322422
Levi-Montalcini's account of nerve growth factor, printed in the same journal that printed Cohen's Nobel lecture. No abstract in PubMed; cited for her discovery of nerve growth factor and as the other half of the 1986 prize. The Nobel Foundation's own page could not be opened for this review; the joint award is cited to [77].
- 49Weltman JK. The 1986 Nobel Prize for Physiology or Medicine awarded for discovery of growth factors: Rita Levi-Montalcini, M.D., and Stanley Cohen, Ph.D.doi:10.2500/108854187779045385 · PMID 3302667
Editorial; no abstract in PubMed. Cited for its title: the 1986 Nobel Prize in Physiology or Medicine went jointly to Levi-Montalcini and Cohen for the discovery of growth factors.
- 50Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, et al. Erlotinib in previously treated non-small-cell lung cancer.doi:10.1056/NEJMoa050753 · PMID 16014882
BR.21: 731 unselected patients after one or two chemotherapy regimens; response 8.9% versus under 1%; median survival 6.7 versus 4.7 months (hazard ratio 0.70). The first survival benefit for this drug class in an unselected population.
- 51Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).doi:10.1016/S0140-6736(05)67625-8 · PMID 16257339
ISEL: 1,692 patients; median survival 5.6 versus 5.1 months (hazard ratio 0.89, P = 0.087), not significant. Preplanned subgroups showed longer survival in never-smokers (8.9 versus 6.1 months) and patients of Asian origin (9.5 versus 5.5 months). Subgroup findings are hypothesis-generating.
- 52Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.doi:10.1056/NEJMoa044238 · PMID 15728811
One patient, in complete remission on gefitinib for two years, relapsed with a second mutation, threonine 790 to methionine (T790M); modeling and biochemistry showed it caused resistance. A case report.
- 53Pao W, Miller VA, Politi KA, Riely GJ, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.doi:10.1371/journal.pmed.0020073 · PMID 15737014
T790M in two of five patients with acquired resistance, and in a sixth who progressed on adjuvant gefitinib; not found in untreated tumors; no KRAS mutations at resistance. The authors noted an analogous mutation in imatinib resistance.
- 54Bell DW, Gore I, Okimoto RA, Godin-Heymann N, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.doi:10.1038/ng1671 · PMID 16258541
One family with multiple non-small-cell lung cancers and germline T790M; four of six tumors analyzed had a second, somatic activating EGFR mutation on the same copy of the gene.
- 55Bonner JA, Harari PM, Giralt J, Azarnia N, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.doi:10.1056/NEJMoa053422 · PMID 16467544
424 patients; radiation plus cetuximab versus radiation alone: locoregional control 24.4 versus 14.9 months; median survival 49.0 versus 29.3 months (hazard ratio 0.74). More acneiform rash and infusion reactions, no more severe mucositis. The comparator was radiation alone, not radiation with cisplatin.
- 56Maemondo M, Inoue A, Kobayashi K, Sugawara S, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.doi:10.1056/NEJMoa0909530 · PMID 20573926
NEJ002, Japan: 230 untreated patients with EGFR mutations; gefitinib versus carboplatin-paclitaxel; progression-free survival 10.8 versus 5.4 months (hazard ratio 0.30); response 73.7% versus 30.7%; median survival 30.5 versus 23.6 months (P = 0.31); one death from interstitial lung disease on gefitinib. Stopped early after a planned interim analysis. The abstract does not describe crossover.
- 57Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.doi:10.1200/JCO.2013.53.5633 · PMID 25154822
891 patients; three-year progression-free survival 61.2% without versus 58.9% with cetuximab, survival 72.9% versus 75.8%; grade 3-4 mucositis 33.3% versus 43.2%; radiation interruptions 15.1% versus 26.9%; tumor EGFR expression did not distinguish outcome.
- 58Thress KS, Paweletz CP, Felip E, Cho BC, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.doi:10.1038/nm.3854 · PMID 25939061
Plasma DNA from patients resistant to osimertinib (then AZD9291): of 15 followed serially, 6 acquired C797S, 5 kept T790M without C797S, and 4 lost T790M. Shows both a new resistance mutation and the use of blood to find it.
- 59Mok TS, Wu YL, Ahn MJ, Garassino MC, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer.doi:10.1056/NEJMoa1612674 · PMID 27959700
AURA3: 419 T790M-positive patients after a first EGFR inhibitor; progression-free survival 10.1 versus 4.4 months (hazard ratio 0.30); response 71% versus 31%; 8.5 versus 4.2 months in 144 with brain metastases; grade 3 or worse adverse events 23% versus 47%. Funded by AstraZeneca.
- 60Mehanna H, Robinson M, Hartley A, Kong A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.doi:10.1016/S0140-6736(18)32752-1 · PMID 30449623
334 low-risk patients: severe toxicity identical (4.8 events per patient in both arms); two-year survival 97.5% with cisplatin versus 89.4% with cetuximab (hazard ratio 5.0); two-year recurrence 6.0% versus 16.1%. Funded by Cancer Research UK. Published online November 2018.
- 61Gillison ML, Trotti AM, Harris J, Eisbruch A, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.doi:10.1016/S0140-6736(18)32779-X · PMID 30449625
849 patients; cetuximab failed non-inferiority: five-year survival 77.9% versus 84.6% with cisplatin; progression-free survival 67.3% versus 78.4%; locoregional failure 17.3% versus 9.9%; moderate to severe toxicity similar. Funded by the National Cancer Institute, Eli Lilly and the Oral Cancer Foundation. Published online November 2018.
- 62Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa1913662 · PMID 31751012
FLAURA final survival: median 38.6 versus 31.8 months (hazard ratio 0.80; 95.05% confidence interval 0.64 to 1.00; P = 0.046). A real but modest gain, with the upper bound of the interval at 1.00. Funded by AstraZeneca.
- 63Wu YL, Tsuboi M, He J, John T, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer.doi:10.1056/NEJMoa2027071 · PMID 32955177
ADAURA: 682 patients after complete resection of stage IB to IIIA disease, three years of osimertinib or placebo. At 24 months, 90% versus 44% of stage II to IIIA patients alive and disease-free (hazard ratio 0.17). Survival immature. Funded by AstraZeneca.
- 64Tsuboi M, Herbst RS, John T, Kato T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC.doi:10.1056/NEJMoa2304594 · PMID 37272535
ADAURA final survival: at five years, 85% versus 73% alive in stage II to IIIA (hazard ratio 0.49) and 88% versus 78% in stage IB to IIIA (hazard ratio 0.49). Funded by AstraZeneca.
- 65Zhou C, Tang KJ, Cho BC, Liu B, et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions.doi:10.1056/NEJMoa2306441 · PMID 37870976
PAPILLON: 308 untreated patients; progression-free survival 11.4 versus 6.7 months (hazard ratio 0.40); response 73% versus 47%; interim survival hazard ratio 0.67 (0.42 to 1.09), not significant; crossover allowed. Funded by Janssen.
- 66Passaro A, Wang J, Wang Y, Lee SH, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.doi:10.1016/j.annonc.2023.10.117 · PMID 37879444
657 patients after osimertinib; progression-free survival 6.3 and 8.3 versus 4.2 months (hazard ratios 0.48 and 0.44); the lazertinib regimen was changed mid-trial for blood toxicity. Many authors were Janssen employees. Published online October 2023.
- 67Fakih MG, Salvatore L, Esaki T, Modest DP, et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C.doi:10.1056/NEJMoa2308795 · PMID 37870968
CodeBreaK 300: 160 patients; progression-free survival 5.6 months (960 mg) versus 2.2 months with standard care (hazard ratio 0.49); response 26.4% versus 0%; skin toxicity and hypomagnesemia most common; survival maturing. Funded by Amgen, with Amgen employees among the authors.
- 68Lu S, Kato T, Dong X, Ahn MJ, et al. Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC.doi:10.1056/NEJMoa2402614 · PMID 38828946
LAURA: 216 patients with unresectable stage III disease who had not progressed after chemoradiotherapy; progression-free survival 39.1 versus 5.6 months (hazard ratio 0.16). Interim survival at 20% maturity: hazard ratio 0.81 (0.42 to 1.56), not significant. Grade 3 or worse adverse events 35% versus 12%; radiation pneumonitis 48% versus 38%. Funded by AstraZeneca.
- 69Yang JC, Lee DH, Lee JS, Fan Y, et al. Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer.doi:10.1200/JCO.23.02747 · PMID 39173098
492 patients; progression-free survival 5.6 versus 5.5 months (hazard ratio 0.80) and survival 15.9 versus 14.7 months (hazard ratio 0.84), neither meeting its significance boundary. Several authors were Merck employees.
- 70He J, Tsuboi M, Weder W, Chen KN, et al. Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer.doi:10.1200/JCO-25-00883 · PMID 40454705
NeoADAURA: 358 patients with resectable stage II-IIIB disease; major pathologic response 26% (osimertinib plus chemotherapy) and 25% (osimertinib) versus 2% (placebo plus chemotherapy); event-free survival 15% mature. The abstract does not define major pathologic response numerically. Three authors were AstraZeneca employees.
- 71Fang W, Wu L, Meng X, Yao Y, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa2512071 · PMID 41124220
OptiTROP-Lung04, China, published online 19 October 2025: 376 patients; progression-free survival 8.3 versus 4.3 months (hazard ratio 0.49); overall survival hazard ratio 0.60, 18-month survival 65.8% versus 48.0%. Funded by Sichuan Kelun-Biotech, with company employees among the authors.
- 72Díaz-Gay M, Zhang T, Hoang PH, Leduc C, et al. The mutagenic forces shaping the genomes of lung cancer in never smokers.doi:10.1038/s41586-025-09219-0 · PMID 40604281
Sherlock-Lung: tumor genomes of 871 treatment-naive never-smokers from 28 locations. KRAS mutations 3.8 times more common in North American and European than East Asian adenocarcinomas; EGFR more common in East Asian; SBS40a enriched with EGFR mutations; higher air pollution associated with more mutations, including a 3.9-fold increase in SBS4, with a dose-response; no association with secondhand smoke. Observational.
- 73Lu S, Wang J, Yang N, Lv D, et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial.doi:10.1016/S0140-6736(25)01811-2 · PMID 41544643
211 patients, all Asian, at 68 Chinese hospitals; progression-free survival 8.2 versus 4.5 months (hazard ratio 0.34) in the whole trial. Funded by HUTCHMED and AstraZeneca, with HUTCHMED employees among the authors.
- 74Hong S, Zhou T, Hou X, et al. Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.doi:10.1016/S0140-6736(26)02026-X · PMID 42933461
432 randomized at 73 sites in China, 422 treated; progression-free survival 11.1 versus 5.7 months (hazard ratio 0.40); grade 3 or worse treatment-related events 79% versus 62%, mostly blood counts; interstitial lung disease in 2 patients; overall survival interim only. Open-label; funded by Baili-Bio, with company staff among the authors.
- 75Xu CR, Zhang Y, Lin G, et al. Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.doi:10.1016/S0140-6736(26)01899-4 · PMID 42933457
498 randomized at 62 sites in China; interim progression-free survival 8.3 versus 5.4 months (hazard ratio 0.47) at a median follow-up of 7.7 months; grade 3 or worse treatment-related events 41% versus 39%. Open-label; funded by Jiangsu Hengrui, with company staff among the authors; survival not yet reported.
- 76Groenestege WM, Thébault S, van der Wijst J, van den Berg D, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.doi:10.1172/JCI31680 · PMID 17671655
A mutation in the EGF gene in a family with inherited renal magnesium wasting misroutes the precursor, so the kidney's EGFR is understimulated and the magnesium channel TRPM6 is not switched on; cetuximab-treated colorectal patients became hypomagnesemic. Establishes EGF as a magnesium-regulating hormone.
- 77Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network.doi:10.1038/35052073 · PMID 11252954
Review of the ErbB network at the moment antibodies and kinase inhibitors against ErbB1 were in late-stage trials; notes that more than 25,000 women had by then received trastuzumab against ErbB2.
- 78Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.doi:10.1126/science.1141478 · PMID 17463250
Cell-line work plus patient specimens: MET amplification in 4 of 18 (22%) resistant tumors; MET drives ERBB3 (HER3)-dependent activation of PI3K.
- 79Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors.doi:10.1038/nrc1970 · PMID 16990857
Review: because of the key role of EGFR signaling in skin, dermatological toxicities have frequently been described with EGFR inhibitors, and can lead to interruption or dose modification.
- 80Ganetzky R, Finn E, Bagchi A, Zollo O, et al. EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features.doi:10.1002/mgg3.156 · PMID 26436111
Two siblings with homozygous p.Gly428Asp: born prematurely with skin and hair abnormalities, multisystem organ failure, death in the neonatal period from intestinal perforation; EGF failed to induce receptor phosphorylation in patient fibroblasts; comparison with a separately reported patient of the same ethnic background and genotype.
- 81Brennan CW, Verhaak RG, McKenna A, Campos B, et al. The somatic genomic landscape of glioblastoma.doi:10.1016/j.cell.2013.09.034 · PMID 24120142
The Cancer Genome Atlas analysis of more than 500 glioblastomas, describing complex rearrangements of signature receptors including EGFR, and arguing from genomic and protein data that inhibiting a pathway is not a reliable substitute for inhibiting the target itself. The abstract gives no EGFR frequency, so none is quoted from it.
- 82Vivanco I, Robins HI, Rohle D, Campos C, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.doi:10.1158/2159-8290.CD-11-0284 · PMID 22588883
About 40% of glioblastomas carry oncogenic EGFR alterations, mostly in the outer domain. Those mutants are poorly inhibited by erlotinib-type drugs that bind the active kinase shape but are potently inhibited, in cells and mice, by drugs that bind the inactive shape. A laboratory explanation for clinical failure, not a clinical result.
- 83Lassman AB, Pugh SL, Wang TJC, Aldape K, et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.doi:10.1093/neuonc/noac173 · PMID 35849035
INTELLANCE-1: about 50% of newly diagnosed glioblastomas are EGFR-amplified; 639 patients; interim survival 18.9 versus 18.7 months (hazard ratio 1.02); progression-free survival 8.0 versus 6.3 months (hazard ratio 0.84); corneal epitheliopathy 94%. Several authors were AbbVie employees.
- 84van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.doi:10.1200/JCO.2008.17.5984 · PMID 19204207
110 patients; six-month progression-free survival 11.4% with erlotinib versus 24% with chemotherapy; no clear biomarker, including EGFRvIII, identified benefit; the authors judged single-agent activity insufficient.
- 85Mair MJ, Bartsch R, Le Rhun E, Berghoff AS, et al. Understanding the activity of antibody-drug conjugates in primary and secondary brain tumours.doi:10.1038/s41571-023-00756-z · PMID 37085569
Review. Depatuxizumab mafodotin, an antibody-drug conjugate against wild-type EGFR and EGFRvIII, gave no definitive overall survival benefit in newly diagnosed or recurrent EGFR-amplified glioblastoma in phase 2 and 3 trials, despite some radiological responses. The phase 3 trial report, INTELLANCE-1, is cited separately [100].
- 86Choi BD, Gerstner ER, Frigault MJ, Leick MB, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma.doi:10.1056/NEJMoa2314390 · PMID 38477966
Three patients. CAR T cells against EGFRvIII that also secrete an engager against wild-type EGFR, infused into the brain's ventricles: no adverse event above grade 3, tumor regression within days, transient in two of the three. First-in-human, investigator-initiated, uncontrolled.
- 87Bagley SJ, Logun M, Fraietta JA, Wang X, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.doi:10.1038/s41591-024-02893-z · PMID 38480922
University of Pennsylvania, six patients: tumor reductions on early scans in all six, none meeting response criteria; early neurotoxicity in all, treated with high-dose dexamethasone and anakinra. Two authors were affiliated with Kite Pharma, a Gilead company.
- 88Chandramohan V, Herndon JE, Barnwal A, Ayasoufi K, et al. EGFR-targeted antibody-toxin conjugate in recurrent glioma: a phase 1 trial.doi:10.1038/s41591-026-04715-w · PMID 42888247
Single-arm, single-site phase 1 of D2C7-ATC, an antibody-toxin conjugate against wild-type EGFR and EGFRvIII infused directly into tumor, in 81 patients: median survival 7.9 months in 72 with IDH-wild-type recurrent glioblastoma; the maximum tolerated dose was exceeded at the top dose. The biomarker associations with longer survival are univariate and untested in a controlled trial.
- 89Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).doi:10.1200/JCO.2010.33.4235 · PMID 21670455
Overall survival did not differ (hazard ratio 0.90 overall; 1.00 in mutation-positive patients), probably because 64.3% of mutation-positive patients given chemotherapy later received an EGFR inhibitor. Mutation was the strongest predictor; high gene copy number without mutation did worse on gefitinib (hazard ratio 3.85, post hoc). EGFR protein expression was analyzed in 365 patients, but the abstract reports no result for it.
- 90Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).PMID 26609494
151 studies, 33,162 patients: 47% mutated in the Asia-Pacific group (range 20% to 76%), 12% in Oceania; higher in women and never-smokers in every region; little or no data from Africa, the Middle East, Central Asia and Central and South America. All three authors were AstraZeneca employees. No DOI registered; PMC4633915.
- 91Hill W, Lim EL, Weeden CE, Lee C, et al. Lung adenocarcinoma promotion by air pollutants.doi:10.1038/s41586-023-05874-3 · PMID 37020004
Three kinds of evidence in one paper: an association between fine particulate matter (PM2.5) and the incidence of EGFR-driven lung cancer in 32,957 cases across four cohorts; mouse models in which pollutants draw in macrophages that release interleukin-1 beta and push EGFR-mutant alveolar cells into a progenitor-like state; and deep sequencing of normal lung from 295 people finding EGFR driver mutations in 18% and KRAS in 53% of samples. The human part is observational.
- 92Yu HA, Arcila ME, Rekhtman N, Sima CS, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.doi:10.1158/1078-0432.CCR-12-2246 · PMID 23470965
Prospective rebiopsy protocol after resistance to erlotinib or gefitinib: T790M in 98 of 155 (63%); small-cell transformation 3%; MET amplification 4 of 75 (5%); HER2 amplification 3 of 24 (13%).
- 93Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.doi:10.1126/scitranslmed.3002003 · PMID 21430269
37 patients rebiopsied at resistance: all kept the original mutation; 5 (14%) had transformed to small-cell lung cancer; in three patients resistance mechanisms were lost off drug.
- 94Planchard D, Jänne PA, Cheng Y, Yang JC, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC.doi:10.1056/NEJMoa2306434 · PMID 37937763
FLAURA2: 557 patients; adding platinum-pemetrexed to osimertinib improved progression-free survival (hazard ratio 0.62); 57% versus 41% alive and progression-free at 24 months; more grade 3 or worse adverse events, from the chemotherapy. Funded by AstraZeneca.
- 95Ahn MJ, Lin SH, Yang CT, Lee JB, et al. Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: final analysis of a global real-world study.doi:10.1016/j.lungcan.2025.108748 · PMID 41151357
Retrospective, 172 patients diagnosed 2016-2019; 78% received chemoradiation alone, with real-world progression-free survival 6.7 months and survival 68.6 months; 86 of 115 who had further treatment received EGFR pills. Two authors were AstraZeneca employees.
- 96Di Federico A, Pecci F, Jeng M, Peroni M, et al. Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.doi:10.1158/1078-0432.CCR-26-0924 · PMID 42446521
Retrospective multicenter cohort of 473 patients: 81 (17.1%) had EGFR amplification (copy number 6 or more) alongside the mutation; response similar (88% versus 83%) but progression-free survival 11.6 versus 19 months and survival 34 versus 40.1 months. Association, not a tested treatment rule.
- 97Leighl NB, Akamatsu H, Lim SM, Cheng Y, et al. Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 study.doi:10.1200/JCO.24.01001 · PMID 38857463
418 patients after osimertinib and platinum chemotherapy; infusion reactions 13% versus 66%; venous thromboembolism 9% versus 14%; first-dose time 4.8 minutes versus 5 hours; survival hazard ratio 0.62, an exploratory end point (nominal P = 0.02). Many authors were Janssen employees.
- 98Ma X, Li G, Li H. Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis.doi:10.3389/fonc.2026.1832920 · PMID 42534809
Nine studies, 1,092 patients. HERTHENA-Lung02 (patritumab deruxtecan, HER3) improved progression-free survival (hazard ratio 0.77) with overall survival immature and no survival benefit shown; the TROP2 conjugate sacituzumab tirumotecan improved both. A secondary source for HERTHENA-Lung02.
- 99Fang W, Zhao Y, Luo Y, Yang R, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial.doi:10.1001/jama.2024.10613 · PMID 38820549
HARMONi-A: 322 patients at 55 sites in China after EGFR pills; progression-free survival 7.1 versus 4.8 months (hazard ratio 0.46); overall survival immature. Several authors were Akeso employees. The first author in PubMed is listed as a group.
- 100Xiong A, Wang L, Chen J, Wu L, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.doi:10.1016/S0140-6736(24)02722-3 · PMID 40057343
Cited only to describe ivonescimab as a bispecific antibody against programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). The trial excluded EGFR-mutant tumors; its results are not used here. Funded by Akeso.
- 101Riess JW, Yu HA, Le X, de Langen AJ, et al. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.doi:10.1016/j.annonc.2026.02.014 · PMID 41780641
Phase 2 platform module, 69 patients: response 43% and 36% at the two doses; median progression-free survival 9.5 and 11.7 months; adjudicated lung inflammation 3% and 15%. Notes datopotamab deruxtecan is approved alone in EGFR-mutated lung cancer. Uncontrolled; AstraZeneca authors.
- 102Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?doi:10.21037/atm.2017.01.32 · PMID 28251125
Commentary on the first FDA-approved liquid biopsy test, which detects EGFR mutations in circulating tumor DNA; summarizes high tissue-plasma concordance in many studies. The approval document itself was not opened. Its abstract gives neither the year nor the name of the approved test.
- 103Rolfo C, Mack P, Scagliotti GV, Aggarwal C, et al. Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer.doi:10.1016/j.jtho.2021.06.017 · PMID 34246791
Consensus statement: plasma circulating tumor DNA is the most studied alternative to tissue genotyping and first entered practice for EGFR mutations; discusses plasma-first versus tissue-first testing.
- 104Chung CH, Mirakhur B, Chan E, Le QT, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.doi:10.1056/NEJMoa074943 · PMID 18337601
25 of 76 cetuximab-treated patients reacted; 17 of them had IgE against cetuximab before the first dose, versus 1 of 51 who did not react. Such IgE was in 20.8% of Tennessee controls, 6.1% in northern California and 0.6% in Boston, and was directed at the sugar galactose-alpha-1,3-galactose on the antibody's Fab portion. Describes cetuximab as a chimeric mouse-human IgG1.
- 105Cunningham D, Humblet Y, Siena S, Khayat D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.doi:10.1056/NEJMoa033025 · PMID 15269313
BOND: 329 patients with irinotecan-refractory disease; response 22.9% with cetuximab plus irinotecan versus 10.8% with cetuximab alone; time to progression 4.1 versus 1.5 months; survival 8.6 versus 6.9 months, not significantly different. No untreated control arm.
- 106Chung KY, Shia J, Kemeny NE, Shah M, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.doi:10.1200/JCO.2005.08.037 · PMID 15677699
Memorial Sloan-Kettering records review: 16 chemotherapy-refractory patients with EGFR-negative tumors given cetuximab outside a trial; 4 major responses (25%). Small retrospective series.
- 107Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.doi:10.1200/JCO.2016.71.9807 · PMID 28165299
Joint pathology-oncology guideline from a systematic review: evidence supports mutational testing of genes in the EGFR signaling pathway as negative predictors of benefit from anti-EGFR antibodies in colorectal cancer. Two panel members were from diagnostics companies (Castle Biosciences, Biocept).
- 108Arnold D, Lueza B, Douillard JY, Peeters M, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.doi:10.1093/annonc/mdx175 · PMID 28407110
Pooled retrospective analysis of 2,159 patients with known side and RAS status: EGFR antibodies improved survival in left-sided tumors (hazard ratio 0.75) but not right-sided (hazard ratio 1.12). The authors advise caution because the analysis is retrospective.
- 109Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.doi:10.1016/S1470-2045(24)00507-2 · PMID 39551064
186 randomized patients in North America; stopped after an interim futility analysis; post hoc two-year progression-free survival 50.6% with durvalumab versus 63.7% with cetuximab (hazard ratio 1.33). Funded by the US National Cancer Institute and AstraZeneca.
- 110Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.doi:10.1200/JCO.2008.21.7828 · PMID 20142600
95 patients: starting moisturizer, sunscreen, topical steroid and doxycycline before the rash cut grade 2 or worse skin toxicity over six weeks from 62% to 29%, with less quality-of-life impairment. Open-label phase 2.
- 111Commins SP, James HR, Kelly LA, Pochan SL, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose.doi:10.1016/j.jaci.2011.02.019 · PMID 21453959
IgE to alpha-gal rose 20-fold or more after tick bites in 3 people followed prospectively; strong correlation with tick-bite histories; common where Amblyomma americanum is common; linked to delayed anaphylaxis to red meat. The authors conclude tick bites are a cause, possibly the only cause, of this IgE in that region.
- 112Brat DJ, Aldape K, French PJ, Louis DN, et al. cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.doi:10.1093/neuonc/noag108 · PMID 42152226
Consensus of the neuropathology working group: among IDH-mutant astrocytomas, EGFR alteration is one of the genetic changes associated with intermediate risk and most consistent with CNS WHO grade 3. Used only for EGFR's role in glioma grading.
This is education, not medical advice. Nothing on this page is written with knowledge of your history, your medications or your risks, and nothing here is a dose. Do not start or stop any treatment on the basis of it — talk to your own physician. Read the full medical disclaimer.

